Page last updated: 2024-08-25

zoledronic acid and Age-Related Osteoporosis

zoledronic acid has been researched along with Age-Related Osteoporosis in 477 studies

Research

Studies (477)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.21)	18.2507
2000's	118 (24.74)	29.6817
2010's	251 (52.62)	24.3611
2020's	107 (22.43)	2.80

Authors

Authors	Studies
Huang, CF; Mao, TY; Shiao, MS	1
Greenspan, SL; Nayak, S	1
Black, DM; Cauley, JA; Ewing, SK; Kim, TY; Nakamura, T; Napoli, N; Reid, IR; Schafer, AL; Shiraki, M; Takeuchi, Y	1
Eastell, R; Khwaja, A; Peel, N; Salam, S; Schini, M; Thomas, E; Toronjo-Urquiza, L; Walsh, JS	1
Du, D; Gu, M; Jin, L; Xu, J; Yang, Z; Zhang, C; Zhao, S; Zhao, T; Zhao, W; Zheng, L	1
Abe, S; Kamatani, T; Kashii, M; Koizumi, K; Kuriyama, K; Mizuno, N; Yamamoto, K; Yoshida, A; Yoshikawa, H	1
Charokopou, M; Javaid, MK; Libanati, C; Pinedo-Villanueva, R; Willems, D; Yehoshua, A	1
Eastell, R; Gossiel, F; Peel, NFA; Ugur, A; Walsh, JS	1
Luo, W; Lv, Q; Xiao, Y; Xu, D; Xu, L; Yang, Q; Zhang, J; Zhou, Y	1
Kang, T; Lee, SH; Park, JH; Park, SY; Suh, SW	1
Bi, F; Meng, J; Shi, M; Wang, C; Wang, Y; Wu, H; Xu, H; Yan, S; Yang, G; Yao, M; Zhou, C; Zhu, H	1
Chang, YF; Hsu, JC; Hsu, YH; Li, CC; Liang, FW; Ou, HT; Peng, ZY; Wu, CH	1
Colarossi, G; Driessen, A; Eschweiler, J; Maffulli, N; Migliorini, F; Oliva, F	1
Chang, CW; Hsu, JC; Hwang, JS; Li, CC; Tai, TW; Wu, CH	1
Chen, G; Hu, Q; Liu, F; Wang, Q; Yao, L; Zhang, L	1
Fan, T; Li, W; Ning, Z; Wang, J; Wang, M; Wen, A; Yang, Z; Yao, M; Zhang, W	1
González Macías, J; Olmos Martínez, JM	1
Baim, S; Bedrose, S; Casagrande, A; Go, MT; Goel, M; Hanna, M; Husni, H; Li, D; Mahrous, P; Morkos, M	1
Fixen, CW; Fixen, DR	1
Du, G; Fan, D; Han, G; Li, H; Li, R; Liu, D; Liu, Q; Song, C; Tao, L; Zhang, M	1
Chen, CH; Chen, WJ; Chen, YM; Chien, LN; Ku, CK; Li, CY; Lin, SY	1
Fu, WZ; He, JW; Wang, C; Wang, WJ; Zhang, ZL	1
Bartsch, R; Borchert, J; Hadji, P; Kossack, N; O'Kelly, J; Pignot, M	1
Hu, L; Li, YF; Luo, C; Qin, SX; Qu, XL; Sheng, ZF; Wan, XM; Wang, QY; Wang, XB; Yue, C	1
Beyer, L; Bolster, MB; Cevallos, S; Espinoza, J; Fan, W; Finkelstein, JS; Garcia, EF; Kronenberg, HM; Leder, BZ; Machado, M	1
Kang, Y; Li, L; Liu, P; Wang, G; Xiong, Y; Zhou, B	1
Huang, J; Li, P; Li, Y; Wu, X	1
McConnell, M; Shieh, A	1
Choquesillo-Lazarte, D; Demadis, KD; Lazarou, S; Turhanen, P; Vassaki, M	1
Chang, YF; Hsu, YH; Hwang, JS; Li, CC; Liang, FW; Wu, CH	1
Greenspan, SL; Haeri, NS; Perera, S	1
Bharucha, T; Case, SJ; Davies, JH; Moon, RJ	1
Ai, W; Wang, Q; Yu, Q; Zeng, P	1
Jakubowski, M; Pokora, M; Ratajczak, M; Sandomierski, M; Voelkel, A; Zielińska, M	1
Ebeling, PR; Nerlekar, N; Rodríguez, AJ	1
Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T	1
Chang, AB; Conwell, LS; Jeffery, TC	1
Choi, SS; Choung, YJ; Jeong, SJ; Kim, H; Lee, CH	1
Atanasova, M; Chakuleska, L; Doytchinova, I; Krasteva, I; Petrova, R; Popov, G; Shkondrov, A; Simeonova, R; Zlateva-Panayotova, N	1
Casati, MZ; Cirano, FR; Corrêa, MG; Messora, MR; Pimentel, SP; Ribeiro, FV; Zamai, RS	1
Bevers, MSAM; Eekhoff, EMW; Elting, MW; Micha, D; Teunissen, BP; Treurniet, S; van den Bergh, JP; Wyers, CE	1
Diffenderfer, BW; Pearman, L; Pyrih, N; Wang, Y; Williams, SA	1
Cai, X; Chai, Z; Chen, J; Dou, R; Du, C; Hu, Y; Jia, F; Liu, X; Liu, Y; Ruan, L; Zhang, J; Zhang, X	1
Arai, K; Kito, Y; Oshita, Y; Saito, K; Sato, S; Takada, J	1
Gruntmanis, U; Riahi, S	1
Bolster, MB; Fan, W; Leder, BZ	1
Chang, YN; Chen, K; Chen, Z; Hu, F; Lei, Y; Li, H; Li, J; Liang, H; Liu, Q; Liu, S; Liu, Y; Lv, L; Wang, Y; Wang, Z; Xie, J; Xing, G; Yao, L; Yuan, H	1
Arora, T; Balasubramanian, A; Bradbury, BD; Curtis, JR; Kim, M; Lin, TC; O'Kelly, J; Spangler, L; Stad, RK; Zhao, H	1
Chang, YF; Cheng, TT; Huang, CF; Hwang, JS; Li, CC; Lu, TH; Shih, CA; Tai, TW; Tsai, YL; Wu, CH	1
Curraj, E; Gonzalez Rodriguez, E	1
Atallah, ÁN; Civile, VT; Gazoni, FM; Santos, FC; Trevisani, VFM	1
Amigues, C; Breuil, V; Drici, MD; Fresse, A; Gauthier, S; Roux, CH; Vieillard, MH	1
Chen, HM; Fu, SH; Hsu, CC; Hwang, JS; Lee, CC; Lin, JW; Lin, SC; Wang, CY; Wu, CH; Yang, RS	1
Karpuz, S	1
Bi, W; Dong, W; Jia, S; Liang, Y; Qi, M; Song, Z; Wen, G; Xie, S; Zhang, Y	1
Corbetta, S; Degradi, C; Dito, G; Guabello, G; Longhi, M; Lugaresi, M	1
Li, YF; Luo, C; Qu, XL; Sheng, ZF; Tian, L; Wang, QY; Xu, LL; Yang, YY; Yue, C	1
Avan, YL; Çakıroğlu, H; Çınar, BM; Keskin, D; Kochai, A; Öz, İ; Pehlivan, H	1
Bonel, H; Everts-Graber, J; Gahl, B; Häuselmann, H; Lehmann, D; Lehmann, T; Reichenbach, S; Studer, U; Ziswiler, HR	1
Chen, HL; Hu, JP; Lan, L; Li, JF; Li, Q	1
Bastounis, A; Bishop, S; Corp, N; Gittoes, N; Griffin, J; Langley, T; Leonardi-Bee, J; Narayanasamy, MJ; Paskins, Z; Sahota, O	1
Liao, Z; Qu, C; Ye, J; Ye, X; Zhan, Q; Zhao, W; Zheng, X	1
Alves Coelho, MC; Brasil d'Alva, C; Gehrke, B; Madeira, M	1
Kim, H; Lee, CH; Park, S; Sik Choi, S; Yoon Byun, S	1
Evangelatos, G; Fragoulis, GE; Iliopoulos, A; Kechagia, M; Zampeli, E	1
Bauer, DC	1
Ding, Y; Fu, GT; Li, CC; Lin, LJ; Lin, SP; Liu, S; Shen, J; Sheng, PY; Wang, K; Xue, YL; Zhang, JX; Zheng, QJ	1
Kumar, A; Qayoom, I; Teotia, AK	1
Baba, N; Iguchi, H; Kawabata, H; Kinowaki, K; Kizawa, R; Kondoh, C; Masuda, J; Miura, Y; Ozaki, Y; Sakamaki, K; Shigekawa, T; Takahashi, M; Takano, T; Tamura, N; Tanabe, Y; Umezu, T	1
Nakamura, T; Ohshige, H; Shiraki, M; Taguchi, A; Tanaka, S	1
Baum, T; Dieckmeyer, M; Einspieler, I; Karampinos, DC; Kirschke, JS; Metz, S; Rohrmeier, A; Rummeny, EJ; Ruschke, S; Schmidmayr, M; Seifert-Klauss, V; Syväri, J; Zimmer, C	1
Evangelatos, G; Fragoulis, GE; Iliopoulos, A	2
Gao, C; Gu, Y; Han, X; Li, S; Ouyang, G; Xiao, L; Xie, J; Zheng, L	1
Chang, Y; Huang, S; Ke, Y; Liang, C; Liang, G; Xiao, D; Zheng, X; Zhu, X; Zhuang, J	1
Choi, NK; Jin, Y; Kim, SC; Lee, H; Park, S; Roh, M; Tsacogianis, TN	1
Abrahamsen, B; Andersen, M; Choudhury, A; Eriksen, EF; Kalsekar, S; Möller, S; Rubin, KH; Zorina, O	1
Jin, ZH; Liao, W; Wang, SF	1
Hsieh, CY; Huang, HK; Sung, SF	1
Isaksson, H; Kumar, A; Lidgren, L; Liu, Y; Qayoom, I; Raina, DB; Širka, A; Tägil, M; Tanner, KE; Tarasevicius, S; Teotia, AK	1
Hu, JB; Lu, CB; Sang, HX; Wang, FQ; Yang, XJ; Yang, Z; Zhang, Y; Zou, JW	1
Johansson, S; Spångeus, A; Woisetschläger, M	1
Black, DM; Cummings, SR; Eriksen, EF; Green, JR; Hosking, DJ; Lyles, KW; Reid, DM; Reid, IR; Russell, RGG; Trechsel, U	1
Aitken, D; Black, D; Cai, G; Host, LV; Jones, G; Keen, HI; Laslett, LL; Winzenberg, T; Wluka, AE	1
Boran, G; Dierking, I; Ege, D; Kamali, AR; Tavakoli, S	1
Catros, S; Châtel, C; Cloitre, A; Devoize, L; Foissac, F; Lesclous, P; Louvet, B; Roux, C	1
Harsløf, T; Langdahl, B; Sølling, AS	2
Dai, X; Deng, Y; Luo, Y; Ma, H; Xie, J	1
Akahoshi, S; Fuse, Y; Katae, Y; Kawasaki, M; Kondo, H; Ogawa, T; Okazaki, Y; Okimoto, N; Sakai, A; Tsukamoto, M; Yamanaka, Y; Yoshioka, T	1
Bliuc, D; Center, JR; Lyles, KW	1
Oryan, A; Sahvieh, S	1
Kasai, H; Mori, Y; Ose, A; Shiraki, M; Tanigawara, Y	1
Abdel Rahman, MO; Abdelrazek, MT; Elkourashy, SA; Fadul, AM; Hamad, AA; Hussein, RM; Kassem, NA; Nashwan, AJ; Poil, AR; Yassin, MA	1
Berry, SD; Daiello, LA; Kiel, DP; Lary, C; Lee, Y; Zullo, AR	1
Bégin, MJ; Biver, E; Ferrari, S; Uebelhart, B	1
Lecler, A; Provost, C; Sené, T	1
Duan, L; Li, XF; Lin, W; Liu, JZ; Ren, DC; Song, M; Zhan, ZR	1
Li, Y; Lin, J; Wang, P; Xie, Y; Xu, H; Yao, X; Zhuang, H	1
Gzhegotskyi, MR; Kostyshyn, LP; Kostyshyn, NM; Mudry, SI	1
da Silva Martins, C; Dantas, HV; de Carvalho Leitão, RF; de Castro Brito, GA; de Sousa Ferreira, VC; de Sousa, FB; de Sousa, FRN; Girão-Carmona, VCC; Goes, P	1
Kimura, T; Minowa, T; Mizushima, A; Takano, H; Uehara, Y; Watanabe, D; Watanabe, K; Yamashita, A; Yoshikawa, S	1
Cheng, YT; Hong, W; Huo, H; Liao, DJ; Liao, J; Ma, H; Tang, ZL; Zellmer, L; Zhou, Q	1
Akatsuka, T; Dohke, T; Iba, K; Saito, A; Takada, J; Takebayashi, T; Yamamoto, O; Yamamura, M; Yamashita, T	1
Almedany, S; Aroussy, NE; Bahlas, S; Gaafary, ME; Galal, S; Hassan, W; Hegazi, MO; Miedany, YE; Nasr, A; Toth, M	1
Jani, C; Page, S; Sehra, S; Ueberroth, J	1
Shapiro, CL	1
Cromer, SJ; D'Silva, KM; Desai, RJ; Kim, SC; Landon, J; Yu, EW	1
Aftring, RP; Alexeeva, E; Alos, N; Cabral, DA; Choudhury, A; Hosszu, E; Jaremko, JL; Kostik, M; Munns, CF; Padidela, R; Rodd, C; Sayyed, S; Sbrocchi, AM; Shaw, NJ; Shenouda, N; Sunkara, G; Taback, S; Thandrayen, K; Ward, LM	1
Hiraishi, K; Kuroda, T; Nakamura, T; Shiraki, M; Sugimoto, T; Suzuki, H; Takeuchi, Y; Tanaka, S	1
Kiviniemi, U; Koski, AM; Löyttyniemi, E; Ryhänen, EM; Schalin-Jäntti, C; Välimäki, MJ	1
Ikari, K; Mochizuki, T; Okazaki, K; Yano, K	1
Bergamaschi, CC; Ferreira, DC; Franquez, RT; Martins, LHI; Motta, RHL; Silva, MT	1
Chen, W; Zhu, M	1
Ferchak, MA; Greenspan, SL; Langmann, GA; Nace, DA; Perera, S; Resnick, NM	1
Chang, Y; Huang, KC; Huang, TW; Lee, MS; Peng, KT; Shih, HN; Wang, CJ	1
Cipriani, C; Clementelli, C; Colangelo, L; Fassino, V; Manai, R; Minisola, S; Nieddu, L; Pepe, J	1
Dempster, DW; Moreira, CA	1
Jiang, Y; Li, L; Li, M; Liu, W; Lv, F; Ma, M; Qiu, Z; Song, Y; Wang, O; Xia, W; Xing, X; Xu, X	1
Allen, MR; Alvarez, MB; Bidwell, JP; Burr, DB; Childress, P; Condon, KW; Davis, H; He, Y; Hernandez-Buquer, S; Plotkin, LI; Robling, AG; Shao, Y; Stayrook, KR; Warden, SJ; Wek, RC; Yang, FC	1
Agrawal, D; Chatterjee, S	1
Gan, F; Ge, Y; Liu, B; Yu, H	1
Chen, J; Ding, Q; Fan, J; Li, Q; Yin, G; Yu, L	1
Crabtree, N; Högler, W; Sahota, J; Sakka, S; Saraff, V; Shaw, NJ	1
Irie, C; Ito, M; Nakamura, T; Ota, Y; Shiraki, M; Sone, T; Tanaka, S	1
Aydogdu, A; Bozoglu, E; Cintosun, U; Doruk, H; Naharci, MI; Safer, U; Tasci, I	1
Liu, X; Lu, E; Mao, C; Qin, A; Xu, X; Zhang, X	1
Ge, XY; Hao, KY; Jiang, X; Lin, Y; Ma, T; Zhang, BR; Zhang, Y	1
Chen, L; Hu, ZH; Pan, Y; Wang, H	1
Bech, M; Guizar-Sicairos, M; Isaksson, H; Mathavan, N; Schaff, F; Tägil, M; Turunen, MJ	1
Herren, D; Kim, SJ; Kohanim, S; Umunakwe, OC	1
Ishiguro, M; Kasai, H; Mori, Y; Ose, A; Serada, M; Shiraki, M; Tanigawara, Y	1
Bersabe, D; Graybill, S; Kaufman, N; Kuiper, BW; Tate, JM	1
Ding, GZ; Tao, ZS; Wang, L; Wu, XJ; Xie, JB; Xu, ZJ; Yang, M; Zhang, X; Zhou, WS	1
Beckett, T; Burkard, D; Kourtjian, E; Messingschlager, C; Padley, M; Sipahi, R; Stubbart, J	1
Yang, L; Yang, M	1
Akbarzadeh, R; Aliasgharian, A; Darvishi-Khezri, H; Fazli, M; Kosaryan, M	1
Gao, C; Wang, S; Wang, Y; Zhao, B; Zhao, C; Zhao, W; Zhao, Z	1
Chen, W; Huang, X; Lin, R; Wu, C; Wu, J; Zhang, X	1
Ito, K	1
Aghaloo, TL; Bezouglaia, O; Boyce, RW; Dry, SM; Dwyer, D; Gkouveris, I; Hadaya, D; Pirih, FQ; Soundia, A; Stolina, M; Tetradis, S	1
Brezin, F; Dousset, B; Feillet, F; Hernandez, M; Lambert, L; Renard, E; Weryha, G; Wiedemann, A	1
Jin, L; Shuai, Y; Tao, Y; Wang, C; Yang, R	1
Ha, YC; Kim, TY; Koo, KH; Lee, YK	1
Arcos, D; Casarrubios, L; de Pablo, D; Díaz-Güemes, I; Enciso, S; Fernández-Tomé, B; Gómez-Cerezo, N; Ortega, L; Portolés, MT; Saiz-Pardo, M; Sánchez-Margallo, FM; Vallet-Regí, M	1
Li, CW; Liang, BC; Liu, K; Liu, Z; Mao, YF; Shi, XL; Wu, LG	1
Bürki, A; Eckelt, U; Ferguson, SJ; Kautz, A; Kneissel, M; Korn, P; Kramer, I; Range, U; Schlottig, F; Schnabelrauch, M; Stadlinger, B; Tödtman, N	1
Bultink, IEM; Lems, WF; Raterman, HG	1
Aft, R; Brufsky, AM; Coleman, RE; Eidtmann, H; Gnant, M; Lind, P; Mauri, D; Polyzos, NP; Swenson, K; Tevaarwerk, AJ; Valachis, A	1
Bismarck, E; Dörsam, J; Ebert, T; Schmitz-Dräger, BJ; Weiss, C	1
Law, SK; Rahimy, E	1
Arita, K; Hashimoto, M; Hotokezaka, H; Nakano, T; Sirisoontorn, I; Tanaka, M; Yoshida, N	1
Burden, AM; Cadarette, SM; Huang, A; Tadrous, M	1
Kähönen, M; Lahtela, J; Laine, HJ; Mäenpää, H; Mattila, P; Pakarinen, TK	1
Dong, W; Hu, J; Li, JP; Li, JY; Li, P; Liao, NN; Qi, MC	1
Lindsay, C	1
Çankaya, M; Dayisoylu, EH; Ersöz, S; Şenel, FÇ; Taskesen, F; Tosun, E; Üngör, C	1
Adami, S; Gatti, D; Ortolani, R; Rossini, M; Tripi, G; Troplini, S; Vella, A; Viapiana, O; Zanotti, R	1
Caldwell, P; Ivanovski, S; Mattheos, N; Petcu, EB; Reher, P	1
Stoopler, ET	1
Arden, NK; Cooper, C; Javaid, MK; Judge, A; Lyles, KW; Prieto-Alhambra, D	1
Bürki, A; Eckelt, U; Ferguson, SJ; Kautz, A; Kneissel, M; Korn, P; Kramer, I; Range, U; Schlottig, F; Schnabelrauch, M; Stadlinger, B; Tödtmann, N	1
Becker, JT; Binkley, N; Buehring, B; Eickhoff, JC; Lang, JM; Liu, G; Malkovsky, M; McNeel, DG; Staab, MJ; Wallace, M; Wilding, G	1
Bhat, MR; Khajuria, DK; Mahapatra, DR; Razdan, R	1
Bereket, C; Kaplan, S; Kosker, H; Sener, I; Tek, M; Turer, A	1
Hayata, A; Ikeda, T; Nakanishi, H	1
Magremanne, M; Reychler, H	1
Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N	1
Biggin, A; Briody, J; Cowell, CT; Munns, CF; Ooi, HL	1
Chen, DC; Chen, Y; Guo, YH; Liu, T; Lu, CY; Wang, Q	1
Gore, E; Kachnic, LA; Kim, HE; Lawton, CA; Martin, AG; Nabid, A; Pugh, SL; Shah, AB; Smith, M; Tai, P	1
Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J	1
Brance, ML; Brun, LR; Di Loreto, VE; Lupo, M; Rigalli, A	1
Agodoa, I; Kruse, M; Orwoll, E; Parthan, A; Silverman, S	1
Abraham, I; Boonen, S; Daci, E; Denhaerynck, K; Devogelaer, JP; Geusens, P; Gielen, E; Hermans, C; Macdonald, K; Vancayzeele, S	1
Cadarette, SM; Juurlink, DN; Krahn, MD; Lévesque, LE; Mamdani, MM; Tadrous, M; Wong, L	1
Baek, SW; Kim, HS; Kong, DY; Park, YS; Ryu, JA	1
Irwig, MS	1
Arkfeld, DG; Ibrahim, M; Metyas, S; Solyman, J; Yeter, KC	1
Kasperk, C; Nawroth, PP; Spiegel, R	1
Baier, M; Bauer, M; Birkholz, K; Hadji, P; Kauka, A; Muth, M; Ziller, M	1
Bernard, L; Ewang, M; Fogelman, I; Hampson, G; Mohamed, Z; Moore, A; Mosali, P; Wajed, J	1
Rizzoli, R; Uebelhart, B	2
Bhagat, S; Guirguis, R; Karanth, M; Maslin, D	1
Bournia, VK; Dania, V; Iliopoulos, A; Konsta, M	1
Al-Rifaiy, MQ; Almas, K; Javed, F; Vohra, F	1
Chen, YC; Hsu, HT; Huang, KF; Li, HY; Tu, CW; Yang, SS	1
Adami, S; Biondan, M; Bonadonna, P; Gatti, D; Idolazzi, L; Orsolini, G; Rossini, M; Tripi, G; Viapiana, O; Zanotti, R	1
Bouvet, A; Caruba, T; Pouchot, J; Sabatier, B; Savoldelli, V	1
Black, DM; Boonen, S; Cosman, F; Cummings, SR; Eastell, R; Palermo, L; Reid, IR	1
Black, DM; Boonen, S; Cauley, JA; Cosman, F; Cummings, SR; Eastell, R; Palermo, L; Reid, IR	1
Bhadada, SK; Bhansali, A; Dhiman, V; Mithal, A; Muthukrishnan, J; Sharma, DC; Sridhar, S	1
Cavallasca, JA; Reyt, C	1
Camacho, PM; Camara, MI; Sheedy, KC	1
Albert, US; Baier-Ebert, M; Hadji, P; Kalder, M; Kyvernitakis, I	1
Khajuria, DK; Mahapatra, DR; Razdan, R	1
Reid, IR	2
Aftring, RP; Black, DM; Cauley, JA; Cosman, F; Cummings, SR; Eastell, R; Hue, TF; Lakatos, P; Leung, PC; Lippuner, K; Mukhopadhyay, A; Reid, IR; Tan, M	1
Bagan, JV; Bagán, L; Carbonell, E; Cibrian, RM; Leopoldo-Rodado, M; Lopez, J; Scully, C; Utrilla, J	1
Burden, AM; Cadarette, SM; Calzavara, A; Tadrous, M	1
El Osta, B; El Osta, L; El Osta, N; Hennequin, M; Lakiss, S	1
Chen, L; Curtis, JR; Delzell, E; Saag, KG; Xie, F; Yun, H	1
Lee, CY; Suzuki, JB	1
Cavaciocchi, F; Ceribelli, A; Crotti, C; De Santis, M; Fabbriciani, G; Generali, E; Massarotti, M; Selmi, C	1
Koy, J; Koy, S; Lauer, G; Ney, M; Sabatowski, R; Schubert, M	1
Ferchak, MA; Greenspan, SL; Nace, DA; Perera, S; Resnick, NM	1
Fulchino, LA; Kim, CA; Kim, DH; Kim, SC; Rogers, JR; Solomon, DH	1
Hu, J; Li, Y; Shui, X; Zhang, L	1
Bonjoch, A; Clotet, B; del Río, L; di Gregorio, S; Echeverría, P; Estany, C; Herrero, C; Negredo, E; Ornelas, A; Pérez-Álvarez, N; Puig, J	1
Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR	1
Che, W; Dong, J; Jiang, L; Li, X; Yasen, M; Yuan, W	1
Baek, HR; Jin, YZ; Lee, JH; Lee, KM; Shin, SJ; Zheng, GB	1
Carvalho, MD; da Silva Martins, J; Grizzo, FM; Jorgetti, V; Pelloso, SM; Pinheiro, MM	1
Cheung, MS	1
Fu, Y; Jiang, Y; Li, M; Meng, XW; Wang, O; Xia, WB; Xing, XP	1
Kim, JW; Kim, MR; Kim, SJ; Landayan, MEA; Tatad, JCI	1
Atherton, PJ; Dakhil, SR; Hines, SL; Lafky, JM; Loprinzi, CL; Majithia, N; Olson, J; Perez, EA; Wagner-Johnston, N	1
George, S; Hummel, K; Kaplan, P; Levine, MA; Monk, HM; Weber, DR	1
Adler, RA; Bauer, DC; Camacho, PM; Clarke, BL; Clines, GA; Compston, JE; Drake, MT; Edwards, BJ; El-Hajj Fuleihan, G; Favus, MJ; Greenspan, SL; McKinney, R; Pignolo, RJ; Sellmeyer, DE	1
Dai, K; Ge, S; Hao, Y; Lu, Y; Mao, Z; Wang, L; Wang, X	1
Faasse, K; Fernandez, J; Grey, A; Horne, A; Kalluru, R; Petrie, KJ; Stephens, MH	1
Aydogdu, A; Bozoglu, E; Cintosun, U; Doruk, H; Meric, C; Naharci, I; Safer, U; Tasci, I	1
Byun, Y; Jeon, OC; Kim, HS; Park, JW; Seo, DH	1
Chen, F; Dai, Z; Jiang, Y; Kang, Y; Keller, ET; Lv, G	1
Akanle, OA; Al-Adhoubi, NK; Al-Bogami, MM; Alkhorayef, MA; Bystrom, J; Jawad, AS; Mageed, RA	1
Al-Agha, AE; Hayatalhazmi, RS	1
Curtin, CM; Duffy, GP; Lee, TC; McCoy, RJ; Mulcahy, LE; O'Brien, FJ; Taylor, D	1
Crincoli, V; Favia, G; Limongelli, L; Maiorano, E; Tempesta, A	1
Aapro, M; Albert, US; Bergh, J; Body, JJ; Cameron, D; Clézardin, P; Coleman, RE; Conte, PF; Cortes, J; Costa, L; Di Leo, A; Diel, I; Dodwell, D; Ejlertsen, B; Gnant, M; Gray, R; Hadji, P; Harbeck, N; Holen, I; Kaufmann, M; Markopoulos, C; Martin, M; Powles, TJ; Santini, D; Smith, I; Thurlimann, B; Untch, M; Wilson, C	1
Čellár, R; Lacko, M; Schreierová, D; Vaško, G	1
Ding, K; Ding, S; Fu, R; Guan, J; Li, L; Liu, H; Liu, Z; Peng, F; Qu, W; Ruan, E; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wang, Y; Wu, Y; Xing, L	1
Cushman, T; Donthireddy, V; Kulkarni, P; Rao, S	1
Cheng, HL; Hsieh, MJ; Lin, CW; Lu, KH; Yang, JS; Yang, SF	1
Chen, LH; Chen, WJ; Fu, TS; Lai, PL; Lin, TY; Niu, CC; Tsai, TT; Yang, SC	1
Aslan, A; Balcı, M; Çırpar, M; Kochai, A; Tulmaç, ÖB; Türker, M	1
Ataoğlu, B; Berkay, AF; Eren, TK; Kaptan, AY; Yapar, AE	1
Negredo, E; Warriner, AH	1
Al-Nofal, A; Kahoud, RJ; Kumar, S; Tebben, PJ; Tripathi, S; Trivedi, S	1
Adami, S; Bonadonna, P; Gatti, D; Idolazzi, L; Kunnathully, V; Orsolini, G; Rossini, M; Tripi, G; Viapiana, O; Zamò, A; Zanotti, R	1
Busetti, J; de Figueiredo, JA; Donos, N; Mardas, N; Mezzomo, LA; Scarparo, RK	1
Lampropoulou-Adamidou, K; Tournis, S; Triantafyllopoulos, IK	1
Bauer, DC; Bell, KJ; Black, DM; Eastell, R; Glasziou, P; Harrison, SL; Hayen, A; Irwig, L	1
Chakrabarti, SS; Gambhir, IS; Kaur, U	1
Gehlen, M; Hinz, C; Lazarescu, AD; Maier, A; Pfeifer, M; Schmidt, N; Schwarz-Eywill, M; Weidemann, HF; Werner, M	1
Easley, KA; Foster, A; Knezevic, A; Lahiri, CD; Lennox, JL; Ofotokun, I; Powers, P; Sanford, SE; Sheth, AN; Titanji, K; Vunnava, A; Ward, L; Weitzmann, MN	1
Mészaros, Á; Veszelyné Kotán, E	2
Hao, X; Jing, D; Liu, J; Luo, E; Meng, G; Xu, F	1
Akpinar, P; Aktas, I; Dogan, Z; Erdogan, O; Ileri, C; Kaysin, MY; Kepez, A; Nazikoglu, C; Ozkan, FU; Saymaz, S	1
Alberts, DS; Greene, MH; Hibler, EA; Kauderer, J; Rodriguez, GC	1
Bruns, DE; Campbell, ST; Santen, RJ	1
Muruganandam, M; Sandhu, H	1
Fukunaga, M; Hagino, H; Ito, M; Kishimoto, H; Nakamura, T; Nakano, T; Ohashi, M; Ota, Y; Shiraki, M; Sone, T; Taguchi, A; Tanaka, S	1
Bartlow, CM; Butt, BB; Damron, TA; Mann, KA; Oest, ME; Zimmerman, ND	1
Choi, NK; Kim, SC; Landon, JE; Solomon, DH; Song, HJ; Tsacogianis, TN	1
Ceausu, I; Depypere, H; Lambrinoudaki, I; Mueck, A; Pérez-López, FR; Rees, M; Senturk, LM; Simoncini, T; Stevenson, JC; Stute, P; Trémollieres, FA; van der Schouw, YT	1
Inderjeeth, AJ; Inderjeeth, CA; Raymond, WD	1
Dhillon, S	1
Bagheri, H; Couture, G; Delzor, F; Laroche, M; Micallef, J; Ruyssen-Witrand, A	1
Karasik, D; Khajuria, DK; Razdan, R; Trebbin, M; Vasireddi, R	1
Nakamura, T; Shiraki, M; Suzuki, H; Tanaka, S; Ueda, S	1
Bell, JM; Beringer, T; Blackwood, B; Elliott, M; Hamilton, A; Quinlivan, R; Shields, MD; Tirupathi, S; Watters, J	1
Boyce, BF; Li, J; Li, X; Pei, L; Sun, W; Wang, M; Wang, Z; Xing, L; Zhang, H	1
Deas, CM; Freeman, MK; Iranikhah, M; Murphy, P	1
Traut, V	1
Cheng, JC; Wong, YK	1
Martens, MG; Shaw, H	1
Bouler, JM; Gauthier, O; Pioletti, DP; Stadelmann, VA; Terrier, A	1
Hagino, H; Hashimoto, J; Katagiri, H; Okano, T	1
Alexakos, P; Christoulas, D; Konstantinidou, M; Terpos, E; Tsiftsakis, E; Voskaridou, E	1
Brafman, L; Cremers, S; Crew, KD; Cucchiara, G; Hershman, DL; Irani, D; McMahon, DJ; Shane, E	1
Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P	1
Hochberg, MC	1
Chapman, I; Ebeling, PR; Greville, H; King, SJ; Kotsimbos, T; Nugent, P; Player, R; Topliss, DJ; Warner, J; Wilson, JW	1
Fukawa, T; Kamiya, S; Wada, S	2
Amanata, N; He, LH; Little, DG; Swain, MV	1
Deeks, ED; Perry, CM	1
Arnol, V; Cortizo, AM; Felice, JI; Gangoiti, MV; McCarthy, AD	1
Bartl, R	2
Ayoub, G; Banal, F; Briot, K; Dougados, M; Roux, C	1
Fernandez, S; Huang, J; McCutchan, JA; Meixner, L	1
Bouxsein, ML; Brouwers, JE; Rietbergen, Bv; Ruchelsman, M	1
Compston, J; Debiram, I; Loveridge, N; Poole, KE; Power, J; Reeve, J; Rose, C; Vedi, S; Warburton, EA	1
Okazaki, R	1
Chae, YS; Kim, JG; Kim, SN; Kim, YJ; Lee, SJ; Moon, JH; Sohn, SK	1
Matsumoto, T	1
Mutschler, W; Schieker, M; Seitz, S	1
Kulkarni, H; Mamtani, M	1
Bertoldo, F; Santini, D; Tonini, G; Vincenzi, B	1
Black, DM; Boonen, S; Cosman, F; Delmas, PD; Eastell, R; Eriksen, EF; Kendler, D; Mesenbrink, PG; Munoz, F; Watts, NB	1
Brown, JJ; Zacharin, MR	1
Bilezikian, JP; Gennari, L	1
Devogelaer, JP; Fashola, T; Ferreira, A; Hartl, F; Lau, CS; Mesenbrink, P; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN	1
Bilalis, A; Boutsikas, G; Christoulas, D; Kastritis, E; Papatheodorou, A; Terpos, E; Varvagiannis, K; Voskaridou, E; Xirakia, C	1
Eufinger, H; Hoefert, S; Schmitz, I; Tannapfel, A	1
Brendel, C; Hamann, C; Hofbauer, LC; Krüger, A; Neubauer, A; Ramaswamy, A; Schnabel, M	1
Silverman, SL	1
Coleman, RE; Winter, MC	1
Gruntmanis, U; Piper, PK	1
Arcenas, AG; Bhoopalam, N; Broderick, WR; Campbell, SC; Friedman, N; Garewal, H; Iyer, P; Moritz, T; Reda, D; Van Veldhuizen, PJ; Warren, S	1
Fazzalari, NL; Le, V; Ma, B; Perilli, E; Reynolds, K; Salmon, P	1
Allen, MR; Burr, DB; Feher, A; Fuchs, RK; Koivunemi, A; Koivunemi, M; Phipps, RJ; Reinwald, S	1
Parr, NJ; Wadhwa, VK; Weston, R	1
Bonfa, E; Caparbo, VF; Carvas, JS; Fuller, P; Lima, LA; Mello, SB; Pereira, RM; Silveira, CA	1
Awad, D; Brafman, L; Cremers, S; Crew, KD; Hershman, DL; McMahon, DJ; Shane, E; Shao, T	1
Abrahamsson, PA; Miller, K; Saad, F	1
Black, DM; Boonen, S; Colón-Emeric, CS; Eastell, R; Eriksen, EF; Haentjens, P; Lyles, KW; Magaziner, JS; Mesenbrink, P	1
Atherton, PJ; Dakhil, SR; Dalton, RJ; Hines, SL; Johnson, DB; Loprinzi, CL; Mattar, BI; Perez, EA; Reddy, PS; Sloan, JA	1
Bolland, MJ; Gamble, GD; Grey, AB; Reid, IR	1
Endo, T; Ichikawa, T; Imamoto, T; Kamiya, N; Kawamura, K; Suzuki, H; Takano, M; Yano, M	1
Akova, T; Dağlioğlu, K; Damlar, I; Esen, E; Kürkçü, M; Yildiz, A	1
Abrahamsen, B; Eiken, PA	1
Bleasel, JF; Craig, SJ; Sullivan, L; Vaile, JH; Youssef, PP	1
Bhoopalam, N; Campbell, SC; Ellis, NK; Friedman, N; Garewal, H; Iyer, P; Moritz, TE; Pandya, M; Reda, DJ; Thottapurathu, L; Vanveldhuizen, P; Warren, SR	1
Bauer, DC; Black, DM; Boonen, S; Bucci-Rechtweg, C; Cauley, J; de Papp, A; Eastell, R; Genant, HK; Kelly, MP; Leung, PC; Palermo, L; Santora, A	1
Shane, E	1
Bubbear, JS; Ferguson-Pell, M; Gall, A; Keen, RW; Middleton, FR; Swaminathan, R	1
Civantos Modino, S; Díaz Guardiola, P; Guijarro de Armas, MG; Montaño Martínez, JM; Pavón de Paz, I; Zubieta Tabernero, J	1
John Camm, A	1
Maricic, M	2
Adler, RA	1
Tan, WW	1
Lindor, KD; Petz, JL; Silveira, MG; Treeprasertsuk, S	1
Adachi, JD; Adler, RA; Brown, J; Bucci-Rechtweg, C; Kendler, D; Mesenbrink, P; Miller, PD; Orwoll, ES; Readie, A; Weinstein, RS	1
Reid, DM	1
Hering, F; Meler, A; Rodrigues, P	1
Aapro, M; Coleman, R; Gnant, M; Hadji, P; Lipton, A	1
Deuber, HJ; Theiss, F	1
Brennan, O; Kennedy, OD; Lee, TC; O'Brien, FJ; Rackard, SM	1
Ahn, JH; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kim, HJ; Kim, JE; Kim, SB; Kim, SY; Lee, KS; Lee, MH; Park, YH; Ro, JS	1
Tang, SC	1
Polyzos, SA	1
Bilezikian, JP; Silva, BC	1
Brennan, O; Kennedy, OD; Lee, TC; McNamara, LM; O'Brien, FJ; Rackard, SM	1
Hamdy, RC	1
Hollstein, S; Hölzle, F; Kriwalsky, MS; Kunkel, M; Maurer, P; Rashad, A; Sandulescu, T; Stricker, I	1
Recknor, C	1
Hwang, S; Kim, OH; Lee, EJ; Lim, SK; Moon, SH; Rhee, Y; Shin, DY	1
Gruber, M; Hamann, C; Hofbauer, LC; Rachner, TD; Tsourdi, E; Ziemssen, T	1
Ludwig, H; Zojer, N	1
Cheng, SJ; Chiang, CP; Jeng, JH; Kok, SH; Lee, JJ; Wang, YP	1
D'Alessio, A; Daniele, G; De Luca, A; Gallo, M; Giordano, P; Lamura, L; Maiello, MR; Normanno, N; Pergameno, M; Perrone, F	1
Chen, J; Liu, ZY; Zhao, LJ	1
Chan, CK; Hou, SM; Ng, CF; Wong, AY; Yee, CH; Yip, SK	1
Boucher, A; Räkel, A; Ste-Marie, LG	1
Bauer, JS; Beck, N; Eitner, S; Kiefer, J; Stockmann, P; Wichmann, M	1
Ahrens, H; Hardes, J; Karst, U; Streitbürger, A; Veldboer, K; Vielhaber, T	1
Abelseth, JM; Bakst, G; Busch, RS; Kane, MP; Traina, AN	1
Bridge, C; Briody, J; Cowell, CT; Hsu, B; Johannesen, J; Little, DG; McQuade, M; Munns, CF; Simm, PJ	1
Ahn, SG; Hwang, SH; Jeong, J; Lee, HD; Lee, HM; Lee, SA	1
Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G	1
Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G	1
Dore, RK	1
Adachi, JD; Boonen, S; Bucci-Rechtweg, C; Claessens, F; Colón-Emeric, CS; Haentjens, P; Kaufman, JM; Lyles, KW; Magaziner, J; Milisen, K; Orwoll, E; Rizzoli, R; Sermon, A; Su, G; Vanderschueren, D; Witvrouw, R	1
Gnant, M	1
Adams, D; Ferchak, M; Fiorito, G; Greenspan, S; Lee, C; Medich, D; Nace, D; Perera, S; Resnick, N; Saul, M; Zukowski, K	1
Black, DM; Boonen, S; Bucci-Rechtweg, C; Cauley, JA; Cosman, F; Cummings, SR; Eastell, R; Hue, TF; Lakatos, P; Leung, PC; Lippuner, K; Man, Z; Martinez, RL; Reid, IR; Ruzycky, ME; Su, G; Tan, M	1
Brandizzi, D; Cabrini, RL; Paparella, ML; Santini-Araujo, E	1
Ha, YC; Koo, KH; Lee, YK; Nho, JH	1
Deng, HO; Li, DF; Wu, W; Xu, L; Zhang, WJ; Zhi, XM	1
Aro, HT; Heervä, E; Peltonen, J; Peltonen, S; Svedström, E; Väänänen, K	1
Bilezikian, JP; Compston, JE	1
Curtis, JR; Delzell, E; Matthews, R; Saag, KG; Yun, H	1
Suzuki, H; Takeuchi, Y	1
Grätz, KW; Jacobsen, C; Metzler, P; Obwegeser, J; Rössle, M; Zemann, W	1
Gupta, SK; Reddy, SV	1
Briody, J; McQuade, M; Munns, CF; Ooi, HL	1
Evangelista, PT; Levine, SM	1
Darendeliler, MA; Gonzales, C; Hashimoto, M; Hotokezaka, H; Luppanapornlarp, S; Sirisoontorn, I; Yoshida, N	1
Freiberger, JJ; Kraft, KH; McGraw, T; Moon, RE; Padilla-Burgos, R; Piantadosi, CA; Stolp, BW; Suliman, HB	1
Chen, DC; Hai-Bin, X; Sun, XH; Tan, L; Wang, R; Zhang, J; Zhao, HX; Zhao, YL	1
Eriksen, EF; Halse, J	1
Deng, H; Wang, X; Wu, W; Xu, L; Zhang, W; Zhi, X	1
Choksi, P; Taxel, P; Van Poznak, C	1
Buffat, H; Guler, S; Hans, D; Lamy, O; Lippuner, K; Perrelet, R; Popp, AW; Senn, C	1
Aubry-Rozier, B; Lamy, O; Lucini, M; Stoll, D	1
Beck Jensen, JE; Brixen, K; Hansen, S; Hauge, EM	1
Adami, S; Fracassi, E; Gatti, D; Idolazzi, L; Ortolani, R; Rossini, M; Tripi, G; Vella, A; Viapiana, O; Zanotti, R	1
Cornish, J; Dalbeth, N; Horne, A; House, ME; Pool, B; Reid, IR; Stewart, A	1
Morgans, AK; Smith, MR	1
Baker, SP; Boskey, AL; Brooks, DJ; Burket, JC; MacLeay, JM; van der Meulen, MC	1
Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A	1
Antunez, O; Boonen, S; Brixen, K; Bucci-Rechtweg, C; Claessens, F; Dimai, HP; Eriksen, E; Hruska, J; Incera, E; Kaufman, JM; Langdahl, B; Lippuner, K; Lipschitz, S; Orwoll, E; Papanastasiou, P; Reginster, JY; Rizzoli, R; Russo, L; Su, G; Vanderschueren, D; Witvrouw, R; Zanchetta, J	1
Chan, JJ; Tong, PL; Yu, LL	1
De Smet, L; Degreef, I; Didden, K; Sciot, R; Vandenberghe, L	1
Collins, LI; Davis, JL; Faccio, R; Mach, RH; Novack, DV; Piwnica-Worms, D; Su, X; Vangveravong, S; Vora, P; Weilbaecher, KN; Yang, C; Zeng, R	1
Bao, CY; Chen, QM; Hu, J; Li, XD; Li, YF; Zhang, H	1
Datta, HK; Hanusch, B; Tuck, SP; Walker, J	1
Bucci-Rechtweg, C; Collette, J; Devogelaer, JP; Goemaere, S; Ish-Shalom, S; Papanastasiou, P; Reginster, JY; Reid, DM; Sambrook, P; Su, G	1
Biskobing, DM; Downs, R; Novy, AM	1
Rotella, DP	1
Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M	1
Body, JJ	1
Eastham, J; Gleason, DM; Shasha, D; Smith, MR; Tchekmedyian, S; Zinner, N	1
Bigos, ST	1
Saad, F	1
Bankhead, C	1
Fröhner, M; Hausmann, R; Wirth, M	1
Athanassiou-Metaxa, M; Garypidou, V; Harsoulis, F; Perifanis, V; Tziomalos, K; Vakalopoulou, S; Vyzantiadis, T	1
DeGrendele, H; Hightower, M; Klem, J	1
Hershman, D; Narayanan, R	1
Borges, CT; Jorgetti, V; Pereira, RM; Souza, SC	1
Colao, A; Lombardi, G; Ricci, P; Rotoli, B; Selleri, C; Serio, B; Tauchmanovà, L	1
Wallace, DJ	1
Kuehn, BM	1
Bagan, JV; Jimenez-Soriano, Y	1
Hande, K; Richardson, PG; Woo, SB	1
Briody, JN; Eisman, JA; Gardiner, EM; Little, DG; McEvoy, A; Smith, EJ; Smith, NC	1
Broumand, V; Fortin, M; Marx, RE; Sawatari, Y	1
Bouler, JM; Bujoli, B; Gauthier, O; Guicheux, J; Janvier, P; Laïb, S; Müller, R; Peter, B; Pioletti, DP; van Lenthe, GH; Zambelli, PY	1
Geusens, P; Reid, D	1
Bleik, JH; El Saghir, NS; Otrock, ZK	1
Abu-Id, MH; Açil, Y; Gottschalk, J; Kreusch, T	1
Angus, PW; Byth, K; Crawford, BA; Handelsman, DJ; Kam, C; McCaughan, GW; Pavlovic, J	1
Altundag, K; Dincer, M; Harputluoglu, H	1
Azar, ST; Habr, D; Inati, A; Koussa, S; Mahfouz, RA; Otrock, ZK; Shamseddeen, WA; Taher, AT	1
Bhatnagar, AS; Evans, DB; Gasser, JA; Green, JR; Ingold, P; Rebmann, A; Shen, V	1
Dolanmaz, D; Karabacakoglu, A; Pampu, AA; Tüz, HH	1
Bergsagel, PL; Carr, AB; Dalton, RJ; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Gollbach, KL; Greipp, PR; Hayman, SR; Kademani, D; Keller, EE; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Stewart, AK; Viozzi, CF; Witzig, TE; Zeldenrust, SR	1
Kademani, D; Koka, S; Lacy, MQ; Rajkumar, SV	1
Weingard, KK	1
Mahachoklertwattana, P	1
Anagnostopoulos, A; Kiamouris, C; Konstantopoulos, K; Spyropoulou, E; Stoupa, E; Terpos, E; Voskaridou, E	1
Athanassiou-Metaxa, M; Garipidou, V; Harsoulis, F; Perifanis, V; Tziomalos, K; Vakalopoulou, S; Vyzantiadis, T	1
Caraglia, M; Santini, D; Tonini, G; Vincenzi, B	1
Doyle-Lindrud, S	1
Carlsten, H; Ohlsson, C; Tarkowski, A; Verdrengh, M	1
Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B	1
Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E	1
Botsis, D; Christodoulakos, G; Lambrinoudaki, I	1
Higano, CS	1
Fallon, MA; Finkelstein, JS; Kantoff, PW; Kaufman, DS; Lee, H; McGovern, FJ; Michaelson, MD; Smith, MR	1
Gogia, N; Kumar, R; Mahapatra, M; Malik, M; Pillai, LS; Puri, T; Sharma, DN	1
Afonso, Y; Bruna, P; Hering, FO; Meller, A; Rodrigues, P	1
Gondo, T; Hashimoto, T; Matsunaga, T; Shigetomi, M; Sugiyama, T; Suzuki, H; Taguchi, T; Tanaka, H	1
Jawad, AS; Shenker, NG	1
Bilezikian, JP; Borba, VZ; Kulak, CA; Paz-Filho, G; Seibel, MJ	1
Bylow, K; Demers, LM; Henderson, TO; Huo, D; Ryan, CW; Stadler, WM; Vogelzang, NJ	1
Goldstein, HR; Gottesman, JE; Hull, GW; Israeli, RS; Lacerna, LV; Rosenberg, SJ; Saltzstein, DR; Tran, DN; Warsi, GM	1
Gralow, JR	1
Bartoletti, R; Cai, T	1
Crescimanno, M; Flandina, C; Leto, G; Tumminello, FM	1
Crawford, B; Gibson, J; Iland, H; Joshua, D; Joy Ho, P; Sanders, J	1
Bonneterre, J; Cortet, B; Facon, T; Maes, JM; Magro, L; Penel, G; Vieillard, MH	1
Costa, L	1
Delmas, PD; Vignot, E	1
Miki, T; Okihara, K	1
Bateman, TA; Lloyd, SA; Lu, T; Travis, ND	1
Bellantoni, M	1
Antoniadou, L; Christoulas, D; Terpos, E; Voskaridou, E	1
Brouwers, JE; Gasser, JA; Huiskes, R; Lambers, FM; van Rietbergen, B	1
Brufsky, AM	2
Nitschmann, S; Ringe, JD	1
Ichikawa, T; Imamoto, T; Kamiya, N; Kawamura, K; Suzuki, H	1
Langdahl, BL; Rejnmark, L	1
Andrada, E; Cánovas, V; Carrato, A; Guillén-Ponce, C; Guirado-Risueño, M; Martín Hidalgo, A; Molina, MA; Molina, MJ; Molina-Garrido, MJ; Mora, A; Pastor, E	1
Avunduk, MC; Dolanmaz, D; Kişnişci, RS; Pampu, AA; Tüz, HH	1
Lewiecki, EM	1
Charafeddine, KM; Mahfouz, RA; Otrock, ZK; Rayes, RF; Taher, AT; Zahed, LF	1
Badalamenti, G; D'Amico, C; Fulfaro, F; Incorvaia, L; Leto, G; Tumminello, FM	1
Delmas, PD	1
Coleman, RE	1
Green, JR	1
Doggrell, SA	1

Reviews

100 review(s) available for zoledronic acid and Age-Related Osteoporosis

Article	Year
Effect of bisphosphonate on hip fracture in patients with osteoporosis or osteopenia according to age: a meta-analysis and systematic review. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2022, Volume: 70, Issue:3 Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Hip Fractures; Humans; Middle Aged; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid	2022
Importance of Time Point-Specific Indirect Treatment Comparisons of Osteoporosis Treatments: A Systematic Literature Review and Network Meta-Analyses. Clinical therapeutics, 2022, Volume: 44, Issue:1 Topics: Bone Density; Bone Density Conservation Agents; Female; Humans; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Teriparatide; Zoledronic Acid	2022
Reduced All-Cause Mortality With Bisphosphonates Among Post-Fracture Osteoporosis Patients: A Nationwide Study and Systematic Review. Clinical pharmacology and therapeutics, 2022, Volume: 112, Issue:3 Topics: Diphosphonates; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Risedronic Acid; Zoledronic Acid	2022
Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis. British medical bulletin, 2022, 09-22, Volume: 143, Issue:1 Topics: Adrenal Cortex Hormones; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Denosumab; Etidronic Acid; Glucocorticoids; Humans; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Zoledronic Acid	2022
Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies. Archives of osteoporosis, 2022, 06-17, Volume: 17, Issue:1 Topics: Aged; Bone Density Conservation Agents; Cardiovascular Diseases; Cohort Studies; Denosumab; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Systematic Reviews as Topic; Zoledronic Acid	2022
Aminobisphosphonates: Reconsideration 25 years after their approval for the treatment of osteoporosis. Medicina clinica, 2022, 10-14, Volume: 159, Issue:7 Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Hydroxyapatites; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Zoledronic Acid	2022
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis. Clinical and investigative medicine. Medecine clinique et experimentale, 2022, 09-21, Volume: 45, Issue:3 Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Male; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Spinal Fractures; Zoledronic Acid	2022
Polypharmacy in Osteoporosis Treatment. Clinics in geriatric medicine, 2022, Volume: 38, Issue:4 Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Polypharmacy; Risedronic Acid; Teriparatide; Zoledronic Acid	2022
Efficacy and Safety of Annual Infusion of Zoledronic Acid and Weekly Oral Alendronate in the Treatment of Primary Osteoporosis: A Meta-Analysis. Journal of clinical pharmacology, 2023, Volume: 63, Issue:4 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid	2023
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis Archives of osteoporosis, 2023, 01-10, Volume: 18, Issue:1 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Male; Neoplasms; Network Meta-Analysis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Zoledronic Acid	2023
Bisphosphonates for osteoporosis in people with cystic fibrosis. The Cochrane database of systematic reviews, 2023, 01-10, Volume: 1 Topics: Adult; Alendronate; Bone Density Conservation Agents; Child; Cystic Fibrosis; Diphosphonates; Female; Fractures, Bone; Humans; Musculoskeletal Pain; Osteoporosis; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid	2023
Risk factors for new vertebral compression fracture after kyphoplasty and efficacy of osteoporosis treatment: A STROBE-compliant retrospective study. Medicine, 2022, Dec-09, Volume: 101, Issue:49 Topics: Calcium; Fractures, Compression; Humans; Kyphoplasty; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; Risk Factors; Spinal Fractures; Treatment Outcome; Vertebroplasty; Zoledronic Acid	2022
Intravenous zoledronate for postmenopausal women with osteopenia and osteoporosis: a systematic review and metanalysis. Sao Paulo medical journal = Revista paulista de medicina, 2023, Volume: 141, Issue:6 Topics: Bone Density; Bone Density Conservation Agents; Brazil; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Zoledronic Acid	2023
Long-term consequences of osteoporosis therapy with bisphosphonates. Archives of endocrinology and metabolism, 2023, Nov-10, Volume: 68 Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Quality of Life; Zoledronic Acid	2023
Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. BMC cancer, 2019, Oct-22, Volume: 19, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Female; Femoral Fractures; Humans; Incidence; Male; Middle Aged; Osteoporosis; Retrospective Studies; Risk Factors; Zoledronic Acid	2019
Drug treatment strategies for osteoporosis in stroke patients. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:7 Topics: Bone Density; Bone Density Conservation Agents; Calcium; Dietary Supplements; Female; Fractures, Bone; Humans; Osteoporosis; Randomized Controlled Trials as Topic; Stroke; Vitamin D; Zoledronic Acid	2020
Bisphosphonates and lifespan. Bone, 2020, Volume: 141 Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Longevity; Osteoporosis; Zoledronic Acid	2020
Effects of bisphosphonates on osteoporosis: Focus on zoledronate. Life sciences, 2021, Jan-01, Volume: 264 Topics: Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Diphosphonates; Humans; Osteoporosis; Treatment Outcome; Zoledronic Acid	2021
[Osteoporosis: Novel drug, new recommendations]. Revue medicale suisse, 2021, Jan-13, Volume: 17, Issue:720-1 Topics: Antibodies, Monoclonal; Bone Density; Denosumab; Drug Approval; Humans; Infusions, Parenteral; Osteoporosis; Osteoporotic Fractures; Switzerland; Zoledronic Acid	2021
Bone-modifying Agents (BMAs) in Breast Cancer. Clinical breast cancer, 2021, Volume: 21, Issue:5 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Osteoporosis; Randomized Controlled Trials as Topic; Zoledronic Acid	2021
Frequency of osteonecrosis in bisphosphonate users submitted to dental procedures: A systematic review. Oral diseases, 2023, Volume: 29, Issue:1 Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Osteonecrosis; Osteoporosis; Zoledronic Acid	2023
Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature. Digital journal of ophthalmology : DJO, 2017, Volume: 23, Issue:4 Topics: Acute Disease; Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Inflammation; Infusions, Intravenous; Orbital Diseases; Osteoporosis; Tomography, X-Ray Computed; Uveitis, Anterior; Zoledronic Acid	2017
Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. Clinical genitourinary cancer, 2018, Volume: 16, Issue:6 Topics: Absorptiometry, Photon; Alendronate; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Femur Neck; Humans; Lumbar Vertebrae; Male; Osteoporosis; Pelvic Bones; Prostatic Neoplasms; Zoledronic Acid	2018
Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis. Drugs, 2019, Volume: 79, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Calcium; Denosumab; Diphosphonates; Exercise Therapy; Female; Glucocorticoids; Humans; Male; Middle Aged; Osteoporosis; Quality of Life; Teriparatide; Treatment Outcome; Vitamin D; Zoledronic Acid	2019
Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. The oncologist, 2013, Volume: 18, Issue:4 Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Fractures, Bone; Humans; Imidazoles; Neoplasm Staging; Osteoporosis; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid	2013
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2014, Volume: 25, Issue:4 Topics: Bone Density Conservation Agents; Diphosphonates; Gastrointestinal Diseases; Humans; Imidazoles; Nausea; Osteoporosis; Randomized Controlled Trials as Topic; Zoledronic Acid	2014
Male hypogonadism and skeletal health. Current opinion in endocrinology, diabetes, and obesity, 2013, Volume: 20, Issue:6 Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Biomarkers; Bone and Bones; Bone Density; Bone Resorption; Denosumab; Diphosphonates; Humans; Hypogonadism; Imidazoles; Immunologic Factors; Klinefelter Syndrome; Male; Men's Health; Osteoporosis; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Testosterone; Zoledronic Acid	2013
The effect of zoledronic acid on the fracture risk in men with osteoporosis. Journal of endocrinological investigation, 2014, Volume: 37, Issue:3 Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Osteoporosis; Risk Assessment; Zoledronic Acid	2014
[Osteoporosis]. Revue medicale suisse, 2014, Jan-15, Volume: 10, Issue:412-413 Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium; Cardiovascular Diseases; Denosumab; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Rickets; Risk Factors; Zoledronic Acid	2014
Efficacy of systemic bisphosphonate delivery on osseointegration of implants under osteoporotic conditions: lessons from animal studies. Archives of oral biology, 2014, Volume: 59, Issue:9 Topics: Alendronate; Animals; Bone Density Conservation Agents; Dental Implantation, Endosseous; Dental Implants; Dental Restoration Failure; Diphosphonates; Female; Ibandronic Acid; Imidazoles; Osseointegration; Osteoporosis; Ovariectomy; Surface Properties; Zoledronic Acid	2014
Predictors of atypical femoral fractures during long term bisphosphonate therapy: a case series & review of literature. The Indian journal of medical research, 2014, Volume: 140, Issue:1 Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Diphosphonates; Female; Femoral Fractures; Humans; Imidazoles; India; Middle Aged; Osteoporosis; Prodromal Symptoms; Retrospective Studies; Zoledronic Acid	2014
[Bisphosphonate-associated osteonecrosis of the jaw]. Schmerz (Berlin, Germany), 2015, Volume: 29, Issue:2 Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Combined Modality Therapy; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Interdisciplinary Communication; Intersectoral Collaboration; Male; Middle Aged; Neoplasms; Osteoporosis; Plasmacytoma; Risk Factors; Tooth Extraction; Treatment Outcome; Zoledronic Acid	2015
Bisphosphonates and risk of cardiovascular events: a meta-analysis. PloS one, 2015, Volume: 10, Issue:4 Topics: Atrial Fibrillation; Bone Density Conservation Agents; Cardiovascular Diseases; Databases, Factual; Diphosphonates; Follow-Up Studies; Humans; Imidazoles; Myocardial Infarction; Odds Ratio; Osteoporosis; Risk; Stroke; Zoledronic Acid	2015
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis. PloS one, 2015, Volume: 10, Issue:5 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Hydroxycholecalciferols; Ibandronic Acid; Imidazoles; Lumbar Vertebrae; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Teriparatide; Thiophenes; Zoledronic Acid	2015
Drugs Used in Paediatric Bone and Calcium Disorders. Endocrine development, 2015, Volume: 28 Topics: Acetazolamide; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitonin; Calcitriol; Calcium; Child; Denosumab; Diphosphonates; Diuretics; Glucocorticoids; Humans; Hypercalcemia; Hyperphosphatemia; Hypocalcemia; Hypophosphatemia; Imidazoles; Osteoporosis; Parathyroid Hormone; Phosphates; Risedronic Acid; Sodium Potassium Chloride Symporter Inhibitors; Vitamin D; Zoledronic Acid	2015
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2016, Volume: 31, Issue:1 Topics: Advisory Committees; Age Factors; Diphosphonates; Female; Femoral Fractures; Humans; Imidazoles; Male; Osteoporosis; Risk Factors; Sex Factors; Spinal Fractures; Zoledronic Acid	2016
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:3 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Consensus; Diphosphonates; Europe; Female; Humans; Imidazoles; Neoplasm Recurrence, Local; Osteoporosis; Surveys and Questionnaires; Zoledronic Acid	2016
Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients. Current opinion in HIV and AIDS, 2016, Volume: 11, Issue:3 Topics: Alendronate; Anti-Inflammatory Agents; Bone Density; Bone Density Conservation Agents; Diphosphonates; HIV Infections; Humans; Imidazoles; Osteoporosis; Zoledronic Acid	2016
Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2016, Volume: 27, Issue:8 Topics: Bone Density; Bone Density Conservation Agents; Cytokines; Diphosphonates; Histamine; Humans; Imidazoles; Mastocytosis; Osteoclasts; Osteoporosis; Prevalence; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Zoledronic Acid	2016
Atypical femoral fracture in a beta-thalassemia major patient with previous bisphosphonate use: case report and a review of the literature. Journal of musculoskeletal & neuronal interactions, 2016, Volume: 16, Issue:1 Topics: Adult; beta-Thalassemia; Bone Density Conservation Agents; Diphosphonates; Femoral Fractures; Humans; Imidazoles; Male; Osteoporosis; Zoledronic Acid	2016
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I]. Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid	2016
Osteoporosis management in patients with breast cancer: EMAS position statement. Maturitas, 2017, Volume: 95 Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Neoplasm Recurrence, Local; Osteoporosis; Premenopause; Zoledronic Acid	2017
Zoledronic Acid (Reclast Drugs, 2016, Volume: 76, Issue:17 Topics: Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Zoledronic Acid	2016
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy. The Cochrane database of systematic reviews, 2017, 01-24, Volume: 1 Topics: Adolescent; Adrenal Cortex Hormones; Bone Density; Bone Density Conservation Agents; Calcium; Child; Child, Preschool; Diphosphonates; Humans; Imidazoles; Male; Muscular Dystrophy, Duchenne; Osteoporosis; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Vibration; Vitamin D; Weight-Bearing; Zoledronic Acid	2017
Retained Skeletal Effects of Zoledronic Acid Following Discontinuation of Treatment: A Review of the Literature. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2017, Mar-01, Volume: 32, Issue:3 Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Humans; Imidazoles; Osteoporosis; Osteoporotic Fractures; Practice Guidelines as Topic; Zoledronic Acid	2017
[Daily practice using the guidelines for prevention and treatment of osteoporosis. Evolution of bisphosphonate therapy. Intravenous injection]. Clinical calcium, 2008, Volume: 18, Issue:8 Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Injections, Intravenous; Osteoporosis; Zoledronic Acid	2008
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates. Current osteoporosis reports, 2008, Volume: 6, Issue:3 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Zoledronic Acid	2008
[Newly developed drugs for osteoporosis in overseas and their future roles for the therapy]. Clinical calcium, 2008, Volume: 18, Issue:10 Topics: Anabolic Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Resorption; Denosumab; Diphosphonates; Drug Design; Evidence-Based Medicine; Fractures, Bone; Humans; Imidazoles; Indoles; Organometallic Compounds; Osteoporosis; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Zoledronic Acid	2008
Zoledronic acid: a review of its use in the treatment of osteoporosis. Drugs & aging, 2008, Volume: 25, Issue:11 Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Male; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid	2008
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates]. Clinical calcium, 2009, Volume: 19, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Patient Compliance; Risedronic Acid; Zoledronic Acid	2009
Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2010, Volume: 21, Issue:1 Topics: Adolescent; Adult; beta-Thalassemia; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Randomized Controlled Trials as Topic; Young Adult; Zoledronic Acid	2010
Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer. Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:4 Topics: Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis; Survival Analysis; Treatment Outcome; Women's Health; Zoledronic Acid	2009
New therapies for osteoporosis: zoledronic acid, bazedoxifene, and denosumab. Current osteoporosis reports, 2009, Volume: 7, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Indoles; Male; Osteoporosis; RANK Ligand; Risk Factors; Treatment Outcome; Zoledronic Acid	2009
Bisphosphonates in breast cancer: teaching an old dog new tricks. Current opinion in oncology, 2009, Volume: 21, Issue:6 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis; Treatment Outcome; Zoledronic Acid	2009
Management of osteoporosis in the aging male: focus on zoledronic acid. Clinical interventions in aging, 2009, Volume: 4 Topics: Aged; Aged, 80 and over; Aging; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; United States; Zoledronic Acid	2009
Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates. BJU international, 2009, Volume: 104, Issue:11 Topics: Adult; Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Osteoporosis; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2009
Effect of osteoporosis treatment on mortality: a meta-analysis. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:3 Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Organometallic Compounds; Osteoporosis; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Treatment Outcome; Zoledronic Acid	2010
[Bone and Men's Health. Bisphosphonate therapy for prostate cancer]. Clinical calcium, 2010, Volume: 20, Issue:2 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Zoledronic Acid	2010
Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. Clinical therapeutics, 2010, Volume: 32, Issue:3 Topics: Animals; Atrial Fibrillation; Bone Density Conservation Agents; Cardiovascular Diseases; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis; Randomized Controlled Trials as Topic; Risk; Zoledronic Acid	2010
The role of zoledronic acid in the management of osteoporosis. Clinical rheumatology, 2010, Volume: 29, Issue:10 Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Osteoporosis; Zoledronic Acid	2010
Update on the use of zoledronic acid in the management of osteoporosis. Current osteoporosis reports, 2010, Volume: 8, Issue:3 Topics: Contraindications; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Kidney; Male; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid	2010
Dosing of zoledronic acid throughout the treatment continuum in breast cancer. Critical reviews in oncology/hematology, 2011, Volume: 79, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Drug Dosage Calculations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Injections, Intravenous; Neoplasm Staging; Osteoporosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome; Zoledronic Acid	2011
[Bisphosphonates in adjuvant therapy of breast cancer]. Medizinische Klinik (Munich, Germany : 1983), 2010, Volume: 105, Issue:9 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Controlled Clinical Trials as Topic; Diphosphonates; Drug Approval; Estrogen Antagonists; Evidence-Based Medicine; Female; Humans; Imidazoles; Neoplasm Staging; Osteoporosis; Pamidronate; Survival Rate; Zoledronic Acid	2010
Women and bone health: maximizing the benefits of aromatase inhibitor therapy. Oncology, 2010, Volume: 79, Issue:1-2 Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Colorectal Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; RANK Ligand; Secondary Prevention; Tamoxifen; Triazoles; Zoledronic Acid	2010
New approaches to the treatment of osteoporosis. Annual review of medicine, 2011, Volume: 62 Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Cathepsin K; Denosumab; Diphosphonates; Drug Therapy, Combination; Duodenum; Female; Fractures, Bone; Genetic Markers; Humans; Imidazoles; Osteoporosis; Parathyroid Hormone; Randomized Controlled Trials as Topic; RANK Ligand; Selective Estrogen Receptor Modulators; Serotonin; Zoledronic Acid	2011
Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug design, development and therapy, 2010, Nov-18, Volume: 4 Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Hypocalcemia; Imidazoles; Kidney; Male; Osteoporosis; Patient Compliance; Zoledronic Acid	2010
Zoledronic acid for prevention and treatment of osteoporosis. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:5 Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Postmenopause; Zoledronic Acid	2011
Supportive therapy in multiple myeloma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 183 Topics: Anemia; Blood Transfusion; Bone Diseases; Calcitonin; Clodronic Acid; Diphosphonates; Erythropoietin; Fractures, Bone; Hematinics; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteoporosis; Pamidronate; Recombinant Proteins; Renal Insufficiency; Zoledronic Acid	2011
Pharmacokinetic evaluation of zoledronic acid. Expert opinion on drug metabolism & toxicology, 2011, Volume: 7, Issue:7 Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Drug Evaluation; Female; Humans; Imidazoles; Osteoporosis; Zoledronic Acid	2011
Role of zoledronic acid in the prevention and treatment of osteoporosis. Clinical interventions in aging, 2011, Volume: 6 Topics: Age Factors; Aging; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Osteoporosis; Osteoporosis, Postmenopausal; Risk Factors; Sex Factors; Zoledronic Acid	2011
Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts. Breast disease, 2011, Volume: 33, Issue:2 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis; Treatment Outcome; Zoledronic Acid	2011
[Combination or sequential treatment using PTH and anti-resorption therapies]. Clinical calcium, 2012, Volume: 22, Issue:3 Topics: Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Teriparatide; Time Factors; Zoledronic Acid	2012
Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: a meta-analysis. Asian Pacific journal of tropical medicine, 2012, Volume: 5, Issue:9 Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid	2012
The management of osteoporosis in breast cancer survivors. Maturitas, 2012, Volume: 73, Issue:4 Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Zoledronic Acid	2012
Bone-targeted agents: preventing skeletal complications in prostate cancer. The Urologic clinics of North America, 2012, Volume: 39, Issue:4 Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Osteoclasts; Osteoporosis; Pamidronate; Prostatic Neoplasms; Quality of Life; Samarium; Toremifene; Zoledronic Acid	2012
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces]. Medicina clinica, 2012, Dec-15, Volume: 139, Issue:15 Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Combined Modality Therapy; Diphosphonates; Disease Susceptibility; Etidronic Acid; Female; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Models, Biological; Neoplasms; Osteitis; Osteoporosis; Retrospective Studies; Risedronic Acid; Zoledronic Acid	2012
Novel therapeutic options for osteoporosis. Current opinion in rheumatology, 2002, Volume: 14, Issue:4 Topics: Animals; Controlled Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Evidence-Based Medicine; Fractures, Spontaneous; Glycoproteins; Humans; Ibandronic Acid; Imidazoles; Norpregnenes; Osteoporosis; Osteoprotegerin; Piperidines; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Selective Estrogen Receptor Modulators; Thiophenes; Zoledronic Acid	2002
Osteoporosis: challenges and new opportunities for therapy. Current opinion in drug discovery & development, 2002, Volume: 5, Issue:4 Topics: Animals; Clinical Trials as Topic; Diphosphonates; Drug Delivery Systems; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Osteoporosis; Parathyroid Hormone; Peptide Fragments; Zoledronic Acid	2002
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer investigation, 2002, Volume: 20 Suppl 2 Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Osteoporosis; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Safety; Zoledronic Acid	2002
Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis. Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:4 Topics: Animals; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Osteoporosis; Randomized Controlled Trials as Topic; Zoledronic Acid	2003
Selected therapy-related clinical research topics in osteoporosis. Journal of pediatric endocrinology & metabolism : JPEM, 2003, Volume: 16 Suppl 3 Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Hip Fractures; Humans; Hypercalcemia; Imidazoles; Injections; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Osteoporosis; Zoledronic Acid	2003
Bisphosphonates: new indications and methods of administration. Current opinion in rheumatology, 2003, Volume: 15, Issue:4 Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Structure-Activity Relationship; Zoledronic Acid	2003
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer. Current oncology reports, 2004, Volume: 6, Issue:4 Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Quality of Life; Risedronic Acid; Risk Factors; Treatment Outcome; Vitamin D; Zoledronic Acid	2004
Rapid prevention of vertebral fractures associated with osteoporosis. Orthopedics, 2005, Volume: 28, Issue:3 Topics: Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Estrogens; Female; Glucocorticoids; Humans; Ibandronic Acid; Imidazoles; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risk Factors; Spinal Fractures; Treatment Outcome; Zoledronic Acid	2005
Newer drug treatments: their effects on fracture prevention. Best practice & research. Clinical rheumatology, 2005, Volume: 19, Issue:6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Denosumab; Diphosphonates; Fractures, Bone; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Organometallic Compounds; Osteoporosis; Osteoprotegerin; Parathyroid Hormone; RANK Ligand; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thiophenes; Zoledronic Acid	2005
[Bisphosphonate-associated osteonecrosis of the jaw]. Mund-, Kiefer- und Gesichtschirurgie : MKG, 2006, Volume: 10, Issue:2 Topics: Aged; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Mandible; Maxilla; Middle Aged; Neoplasms; Osteoporosis; Pamidronate; Risk Factors; Zoledronic Acid	2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clinic proceedings, 2006, Volume: 81, Issue:8 Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Minnesota; Multiple Myeloma; Osteoporosis; Pamidronate; Practice Guidelines as Topic; Zoledronic Acid	2006
Nursing implications of androgen deprivation therapy-associated bone loss. Urologic nursing, 2006, Volume: 26, Issue:4 Topics: Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; Exercise Therapy; Fractures, Bone; Health Promotion; Humans; Imidazoles; Life Style; Male; Morbidity; Nurse's Role; Nursing Assessment; Osteoporosis; Patient Education as Topic; Prostatic Neoplasms; Risk Factors; Vitamin D; Zoledronic Acid	2006
Implications of androgen-deprivation therapy in patients with prostate cancer: A case study. Clinical journal of oncology nursing, 2006, Volume: 10, Issue:5 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Combined Modality Therapy; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Jaw Diseases; Leuprolide; Male; Orchiectomy; Osteonecrosis; Osteoporosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Conformal; Risk Factors; Tomography, X-Ray Computed; Zoledronic Acid	2006
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug safety, 2006, Volume: 29, Issue:12 Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Osteonecrosis; Osteoporosis; Risedronic Acid; Zoledronic Acid	2006
Bisphosphonates. Annals of the New York Academy of Sciences, 2006, Volume: 1092 Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid	2006
Bisphosphonates: reducing the risk of skeletal complications from bone metastasis. Breast (Edinburgh, Scotland), 2007, Volume: 16 Suppl 3 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Neoplasm Staging; Osteoporosis; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid	2007
[New bone density conservation agents for osteoporosis under research and development: Zoledronate]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Design; Humans; Imidazoles; Osteoporosis; Research; Zoledronic Acid	2007
[Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Male; Osteoporosis; Practice Guidelines as Topic; Prognosis; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Zoledronic Acid	2007
Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. The oncologist, 2008, Volume: 13, Issue:2 Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Zoledronic Acid	2008
Zoledronic acid for cancer therapy--induced and postmenopausal bone loss. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:6 Topics: Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid	2008
[Bony lesion with prostate cancer]. Clinical calcium, 2008, Volume: 18, Issue:4 Topics: Antibodies, Monoclonal; Azepines; Bone Neoplasms; Cathepsin K; Cathepsins; Diphosphonates; Enzyme Inhibitors; Humans; Imidazoles; Male; Matrix Metalloproteinases; Osteoclasts; Osteolysis; Osteoporosis; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; RANK Ligand; Sulfones; Zoledronic Acid	2008
Intravenous zoledronic acid for the treatment of osteoporosis. Current osteoporosis reports, 2008, Volume: 6, Issue:1 Topics: Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Fractures, Bone; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis; Risk Factors; Zoledronic Acid	2008
Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Seminars in oncology, 2001, Volume: 28, Issue:2 Suppl 6 Topics: Animals; Bone and Bones; Bone Resorption; Diphosphonates; Drug Evaluation, Preclinical; Humans; Imidazoles; Models, Animal; Osteoporosis; Zoledronic Acid	2001
Zoledronate once-yearly increases bone mineral density--implications for osteoporosis. Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:7 Topics: Bone Density; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Injections, Intravenous; Male; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid	2002

Trials

84 trial(s) available for zoledronic acid and Age-Related Osteoporosis

Article	Year
The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2022, Volume: 37, Issue:1 Topics: Acute-Phase Reaction; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Osteoporosis; Zoledronic Acid	2022
Combination of Calcitriol and Zoledronic Acid on PINP and Disease markers, 2022, Volume: 2022 Topics: Calcitriol; Diabetes Mellitus; Fractures, Avulsion; Humans; Osteoporosis; Pain; Tibial Fractures; Treatment Outcome; Zoledronic Acid	2022
Reduction effect of oral pravastatin on the acute phase response to intravenous zoledronic acid: protocol for a real-world prospective, placebo-controlled trial. BMJ open, 2022, 07-13, Volume: 12, Issue:7 Topics: Acute-Phase Reaction; Female; Humans; Meta-Analysis as Topic; Osteoporosis; Pravastatin; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid	2022
Effect of Teriparatide Versus Zoledronate on Posterior Lumbar Interbody Fusion in Postmenopausal Women with Osteoporosis. World neurosurgery, 2022, Volume: 167 Topics: Bone Density; Bone Density Conservation Agents; Female; Humans; Lumbar Vertebrae; Osteoporosis; Postmenopause; Spinal Fusion; Teriparatide; Treatment Outcome; Zoledronic Acid	2022
Does Zoledronic Acid Improve Appendicular Lean Mass in Older Women with Osteoporosis? A Sub-Analysis of a Randomized Clinical Trial. The Journal of frailty & aging, 2022, Volume: 11, Issue:4 Topics: Aged; Aged, 80 and over; Bone Density; Double-Blind Method; Female; Humans; Osteoporosis; Sarcopenia; Zoledronic Acid	2022
Improved periodontal disease and prevention of tooth loss in osteoporosis patients receiving once-yearly zoledronic acid: a randomized clinical trial. Menopause (New York, N.Y.), 2019, Volume: 26, Issue:11 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Drug Administration Schedule; Female; Humans; Male; Osteoporosis; Periodontal Diseases; Tooth Loss; Treatment Outcome; Zoledronic Acid	2019
Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients. Journal of orthopaedic surgery and research, 2019, Dec-10, Volume: 14, Issue:1 Topics: Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Osteoporosis; Zoledronic Acid	2019
Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2020, Volume: 35, Issue:10 Topics: Bone Density; Bone Density Conservation Agents; Bone Remodeling; Denosumab; Diphosphonates; Humans; Osteoporosis; Zoledronic Acid	2020
Prediction of Fracture Risk From Early-Stage Bone Markers in Patients With Osteoporosis Treated With Once-Yearly Administered Zoledronic Acid. Journal of clinical pharmacology, 2021, Volume: 61, Issue:5 Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Method; Female; Humans; Lumbar Vertebrae; Male; Osteoporosis; Osteoporotic Fractures; Risk Factors; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid	2021
Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis. Medicine, 2020, Dec-18, Volume: 99, Issue:51 Topics: beta-Thalassemia; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Denosumab; Humans; Osteoporosis; Randomized Controlled Trials as Topic; Zoledronic Acid	2020
Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression. Molecular medicine (Cambridge, Mass.), 2021, 02-26, Volume: 27, Issue:1 Topics: Adult; Anti-Retroviral Agents; Bone Density; Bone Density Conservation Agents; Cell Proliferation; Cells, Cultured; Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; Female; HIV Infections; Humans; Male; MAP Kinase Signaling System; MicroRNAs; Middle Aged; Osteoclasts; Osteogenesis; Osteoporosis; RANK Ligand; Smad3 Protein; Tenofovir; Zoledronic Acid	2021
Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2021, Volume: 36, Issue:7 Topics: Bone Density; Bone Density Conservation Agents; Denosumab; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid	2021
Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-induced Osteoporosis: A Randomized, Double-blind, Phase 3 Trial. The Journal of clinical endocrinology and metabolism, 2021, 11-19, Volume: 106, Issue:12 Topics: Adolescent; Bone Density Conservation Agents; Child; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Osteoporosis; Prognosis; Zoledronic Acid	2021
Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study. Calcified tissue international, 2021, Volume: 109, Issue:6 Topics: Acute-Phase Reaction; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Japan; Osteoporosis; Zoledronic Acid	2021
Postoperative zoledronic acid for osteoporosis in primary hyperparathyroidism: a randomized placebo-controlled study. European journal of endocrinology, 2021, Aug-27, Volume: 185, Issue:4 Topics: Aged; Bone Density; Bone Density Conservation Agents; Combined Modality Therapy; Double-Blind Method; Drug Administration Schedule; Female; Finland; Humans; Hyperparathyroidism, Primary; Male; Middle Aged; Osteoporosis; Parathyroidectomy; Postoperative Period; Treatment Outcome; Zoledronic Acid	2021
Safety and Efficacy of Zoledronic Acid Treatment with and without Acetaminophen and Eldecalcitol for Osteoporosis. Internal medicine (Tokyo, Japan), 2021, Volume: 60, Issue:16 Topics: Acetaminophen; Bone Density; Bone Density Conservation Agents; Diphosphonates; Humans; Osteoporosis; Vitamin D; Zoledronic Acid	2021
Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial. BMC musculoskeletal disorders, 2017, 05-22, Volume: 18, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Prospective Studies; Zoledronic Acid	2017
Clinical Efficacy Analysis of Percutaneous Kyphoplasty Combined with Zoledronic Acid in the Treatment and Prevention of Osteoporotic Vertebral Compression Fractures. Journal of investigative surgery : the official journal of the Academy of Surgical Research, 2018, Volume: 31, Issue:5 Topics: Aged; Aged, 80 and over; Back Pain; Bone Density Conservation Agents; Combined Modality Therapy; Female; Follow-Up Studies; Fractures, Compression; Humans; Kyphoplasty; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; Spinal Fractures; Treatment Outcome; Zoledronic Acid	2018
The effect of once-yearly zoledronic acid on hip structural and biomechanical properties derived using computed tomography (CT) in Japanese women with osteoporosis. Bone, 2018, Volume: 106 Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Imidazoles; Osteoporosis; Placebo Effect; Tomography, X-Ray Computed; Zoledronic Acid	2018
Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018, Volume: 29, Issue:5 Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lumbar Vertebrae; Male; Models, Biological; Osteoporosis; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid	2018
Early initiation of zoledronic acid does not impact bone healing or clinical outcomes of hallux valgus orthomorphia. The Journal of international medical research, 2018, Volume: 46, Issue:8 Topics: Aged; Arthrodesis; Bone Density Conservation Agents; Female; Hallux Valgus; Humans; Middle Aged; Osteoporosis; Osteotomy; Postmenopause; Prospective Studies; Treatment Outcome; Zoledronic Acid	2018
Study on Zoledronic Acid Reducing Acute Bone Loss and Fracture Rates in Elderly Postoperative Patients with Intertrochanteric Fractures. Orthopaedic surgery, 2019, Volume: 11, Issue:3 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Drug Administration Schedule; Female; Follow-Up Studies; Fracture Fixation, Intramedullary; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Postoperative Care; Recurrence; Secondary Prevention; Treatment Outcome; Zoledronic Acid	2019
Effect of immobilization, off-loading and zoledronic acid on bone mineral density in patients with acute Charcot neuroarthropathy: a prospective randomized trial. Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons, 2013, Volume: 19, Issue:2 Topics: Acute Disease; Adult; Aged; Arthropathy, Neurogenic; Bone Density; Bone Density Conservation Agents; Casts, Surgical; Diphosphonates; Female; Humans; Imidazoles; Immobilization; Male; Middle Aged; Osteoporosis; Prospective Studies; Weight-Bearing; Zoledronic Acid	2013
Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2014, Volume: 25, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Cognition Disorders; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Hip Fractures; Humans; Imidazoles; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Psychiatric Status Rating Scales; Secondary Prevention; Treatment Outcome; Zoledronic Acid	2014
A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy. Clinical genitourinary cancer, 2013, Volume: 11, Issue:4 Topics: Aged; Alkaline Phosphatase; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Cell Proliferation; Diphosphonates; Drug Administration Schedule; Goserelin; Humans; Imidazoles; Leuprolide; Lymphocyte Count; Male; Middle Aged; Osteoporosis; Prostate-Specific Antigen; Prostatic Neoplasms; T-Lymphocytes; Zoledronic Acid	2013
Intravenous zoledronic Acid given every 6 months in childhood osteoporosis. Hormone research in paediatrics, 2013, Volume: 80, Issue:3 Topics: Adolescent; Bone Density Conservation Agents; Child; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Male; Osteoporosis; Retrospective Studies; Time Factors; Zoledronic Acid	2013
RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients. Prostate cancer and prostatic diseases, 2013, Volume: 16, Issue:4 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Osteoporosis; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2013
Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid. Calcified tissue international, 2014, Volume: 94, Issue:3 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteitis Deformans; Osteoporosis; Treatment Outcome; Zoledronic Acid	2014
Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2014, Volume: 25, Issue:4 Topics: Adult; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Double-Blind Method; Female; Femur; Humans; Imidazoles; Lumbar Vertebrae; Middle Aged; Osteoporosis; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Young Adult; Zoledronic Acid	2014
Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2015, Volume: 30, Issue:3 Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis; Placebos; Zoledronic Acid	2015
Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Osteoporosis; Postmenopause; Risk Assessment; Treatment Outcome; Zoledronic Acid	2014
Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2015, Volume: 26, Issue:1 Topics: Absorptiometry, Photon; Adult; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Lumbar Vertebrae; Middle Aged; Osteoporosis; Premenopause; Zoledronic Acid	2015
The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2015, Volume: 30, Issue:5 Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis; Osteoporotic Fractures; Peptide Fragments; Procollagen; Time Factors; Zoledronic Acid	2015
Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA internal medicine, 2015, Volume: 175, Issue:6 Topics: Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis; Zoledronic Acid	2015
Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years. HIV medicine, 2015, Volume: 16, Issue:7 Topics: Absorptiometry, Photon; Antiretroviral Therapy, Highly Active; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Directive Counseling; Dose-Response Relationship, Drug; Drug Administration Schedule; Feeding Behavior; Female; HIV Infections; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Pelvic Bones; Pilot Projects; Treatment Outcome; Zoledronic Acid	2015
3-D bone models to improve treatment initiation among patients with osteoporosis: A randomised controlled pilot trial. Psychology & health, 2016, Volume: 31, Issue:4 Topics: Aged; Alendronate; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Imidazoles; Male; Models, Anatomic; Osteoporosis; Patient Acceptance of Health Care; Patient Education as Topic; Pilot Projects; Zoledronic Acid	2016
Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2016, Volume: 27, Issue:4 Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Disability Evaluation; Double-Blind Method; Female; Femur Neck; Fractures, Compression; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteogenesis; Osteoporosis; Postoperative Care; Prospective Studies; Spinal Fusion; Spondylolisthesis; Tomography, X-Ray Computed; Treatment Outcome; Wound Healing; Zoledronic Acid	2016
Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2016, Volume: 31, Issue:9 Topics: Biomarkers; Bone Density; Bone Remodeling; Diphosphonates; Humans; Imidazoles; Osteoporosis; Placebos; Reproducibility of Results; Risk Factors; Zoledronic Acid	2016
A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, Sep-01, Volume: 63, Issue:5 Topics: Adult; Anti-Retroviral Agents; Bone Density Conservation Agents; Diphosphonates; Female; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; RNA, Viral; Zoledronic Acid	2016
Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study. Menopause (New York, N.Y.), 2016, Volume: 23, Issue:11 Topics: Adult; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Ovarian Neoplasms; Ovariectomy; Premenopause; Risk Factors; Zoledronic Acid	2016
Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study). Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2017, Volume: 28, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Japan; Male; Osteoporosis; Osteoporotic Fractures; Spinal Fractures; Treatment Outcome; Zoledronic Acid	2017
Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis. Journal of bone and mineral metabolism, 2017, Volume: 35, Issue:6 Topics: Aged; Asian People; Biomarkers; Body Temperature; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Demography; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteogenesis; Osteoporosis; Single-Blind Method; Zoledronic Acid	2017
Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica, 2008, Volume: 93, Issue:10 Topics: Adult; Biomarkers; Bone Density; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Osteoporosis; Pain; Thalassemia; Time Factors; Zoledronic Acid	2008
Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-10, Volume: 26, Issue:29 Topics: Adult; Antineoplastic Agents; Biomarkers; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Osteoporosis; Premenopause; Zoledronic Acid	2008
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. The Lancet. Oncology, 2008, Volume: 9, Issue:9 Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Linear Models; Nitriles; Osteoporosis; Premenopause; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid	2008
Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF). Clinical endocrinology, 2009, Volume: 70, Issue:6 Topics: Adult; Bone Density; Bone Density Conservation Agents; Cystic Fibrosis; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Osteoporosis; Placebos; Zoledronic Acid	2009
A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS (London, England), 2009, Jan-02, Volume: 23, Issue:1 Topics: Adult; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Calcium, Dietary; Diphosphonates; Double-Blind Method; Female; Hip Joint; HIV Infections; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Treatment Outcome; Zoledronic Acid	2009
Bone structure and remodelling in stroke patients: early effects of zoledronate. Bone, 2009, Volume: 44, Issue:4 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Hemiplegia; Hip; Humans; Ilium; Imidazoles; Male; Microscopy, Fluorescence; Middle Aged; Osteoclasts; Osteoporosis; Stroke; Zoledronic Acid	2009
Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients. Bone marrow transplantation, 2009, Volume: 44, Issue:1 Topics: Adolescent; Adult; Aged; Bone Density; Bone Density Conservation Agents; Chronic Disease; Diphosphonates; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Pilot Projects; Stem Cell Transplantation; Steroids; Transplantation, Homologous; Zoledronic Acid	2009
Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. Journal of pediatric endocrinology & metabolism : JPEM, 2009, Volume: 22, Issue:1 Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Child; Child Development; Child, Preschool; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Kidney; Liver; Male; Osteogenesis Imperfecta; Osteoporosis; Pamidronate; Treatment Outcome; Zoledronic Acid	2009
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet (London, England), 2009, Apr-11, Volume: 373, Issue:9671 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Least-Squares Analysis; Male; Middle Aged; Osteoporosis; Risedronic Acid; Treatment Outcome; Young Adult; Zoledronic Acid	2009
Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. The Journal of urology, 2009, Volume: 182, Issue:5 Topics: Aged; Androgen Antagonists; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Male; Osteoporosis; Prostatic Neoplasms; Risk Factors; Veterans; Zoledronic Acid	2009
Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer. BJU international, 2010, Volume: 105, Issue:8 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Density Conservation Agents; Diphosphonates; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Nitriles; Osteoporosis; Prospective Studies; Prostatic Neoplasms; Tosyl Compounds; Zoledronic Acid	2010
Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:2 Topics: Adult; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Premenopause; Zoledronic Acid	2010
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. Breast (Edinburgh, Scotland), 2010, Volume: 19, Issue:2 Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Risk Factors; Treatment Outcome; Triazoles; Zoledronic Acid	2010
Early treatment with zoledronic acid prevents bone loss at the hip following acute spinal cord injury. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2011, Volume: 22, Issue:1 Topics: Adolescent; Adult; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Hip Joint; Humans; Imidazoles; Lumbar Vertebrae; Male; Osteoporosis; Spinal Cord Injuries; Young Adult; Zoledronic Acid	2011
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2010, Volume: 25, Issue:10 Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Treatment Outcome; Zoledronic Acid	2010
Titration of dosage for the protective effect of zoledronic acid on bone loss in patients submitted to androgen deprivation therapy due to prostate cancer: a prospective open-label study. Urologia internationalis, 2010, Volume: 85, Issue:2 Topics: Absorptiometry, Photon; Adenocarcinoma; Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Brazil; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Lumbar Vertebrae; Male; Neoplasm Recurrence, Local; Osteoporosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Time Factors; Treatment Outcome; Zoledronic Acid	2010
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01). Breast cancer research and treatment, 2011, Volume: 125, Issue:1 Topics: Absorptiometry, Photon; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Femur Neck; Humans; Imidazoles; Infusions, Intravenous; Lumbar Vertebrae; Osteoporosis; Premenopause; Prospective Studies; Republic of Korea; Time Factors; Treatment Outcome; Zoledronic Acid	2011
Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer. Asia-Pacific journal of clinical oncology, 2011, Volume: 7, Issue:2 Topics: Aged; Androgen Antagonists; Asian People; Bone Density; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Zoledronic Acid	2011
Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients. Breast cancer research and treatment, 2011, Volume: 130, Issue:3 Topics: Adult; Aged; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Korea; Middle Aged; Osteoporosis; Postmenopause; Zoledronic Acid	2011
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, Volume: 23, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Lumbar Vertebrae; Male; Menopause; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Prednisone; Risedronic Acid; Sex Factors; Vitamin D; Young Adult; Zoledronic Acid	2012
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone, 2012, Volume: 50, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Etidronic Acid; Femur Neck; Glucocorticoids; Hip Joint; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Risedronic Acid; Young Adult; Zoledronic Acid	2012
Once-yearly zoledronic acid in older men compared with women with recent hip fracture. Journal of the American Geriatrics Society, 2011, Volume: 59, Issue:11 Topics: Absorptiometry, Photon; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Hip Fractures; Humans; Imidazoles; Incidence; Injections, Intravenous; Male; Osteoporosis; Prevalence; Time Factors; Treatment Outcome; Zoledronic Acid	2011
Lessons learned from an osteoporosis clinical trial in frail long-term care residents. Clinical trials (London, England), 2012, Volume: 9, Issue:2 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Frail Elderly; Humans; Imidazoles; Male; Osteoporosis; Patient Selection; Pennsylvania; Residential Facilities; Zoledronic Acid	2012
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2012, Volume: 27, Issue:2 Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Incidence; Osteoporosis; Osteoporotic Fractures; Peptide Fragments; Procollagen; Time Factors; Treatment Outcome; Zoledronic Acid	2012
What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:7 Topics: Aged; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Combined Modality Therapy; Debridement; Diphosphonates; Female; Follow-Up Studies; Gingiva; Humans; Hyperbaric Oxygenation; Imidazoles; Male; Multiple Myeloma; Osteoporosis; Pain Management; Pamidronate; Prospective Studies; Quality of Life; Treatment Outcome; Wound Healing; Zoledronic Acid	2012
[Therapeutic effect of zoledronic acid on primary osteoporosis in elderly patients]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2012, Volume: 32, Issue:9 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Osteoporosis; Treatment Outcome; Zoledronic Acid	2012
Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2013, Volume: 28, Issue:3 Topics: Absorptiometry, Photon; Aged; Bone Density; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Placebos; Postmenopause; Retrospective Studies; Spine; Zoledronic Acid	2013
No reduction in circulating preosteoclasts 18 months after treatment with zoledronate: analysis from a randomized placebo controlled trial. Calcified tissue international, 2013, Volume: 92, Issue:1 Topics: Acid Phosphatase; Aged; Bone Density Conservation Agents; Bone Resorption; CD11b Antigen; Diphosphonates; Female; Flow Cytometry; Humans; Imidazoles; Isoenzymes; Leukocytes, Mononuclear; Lipopolysaccharide Receptors; Macrophage Colony-Stimulating Factor; Middle Aged; Osteoclasts; Osteoporosis; Placebos; RANK Ligand; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid	2013
Fracture risk and zoledronic acid therapy in men with osteoporosis. The New England journal of medicine, 2012, 11-01, Volume: 367, Issue:18 Topics: Aged; Aged, 80 and over; Analysis of Variance; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Humans; Hypogonadism; Imidazoles; Logistic Models; Male; Middle Aged; Osteoporosis; Risk; Spinal Fractures; Testosterone; Zoledronic Acid	2012
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids. Rheumatology (Oxford, England), 2013, Volume: 52, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Prednisone; Risedronic Acid; Treatment Outcome; Zoledronic Acid	2013
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. The Journal of urology, 2003, Volume: 169, Issue:6 Topics: Aged; Androgen Antagonists; Bone Density; Diphosphonates; Double-Blind Method; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Zoledronic Acid	2003
Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:2 Topics: Adolescent; Adult; Bone Density; Bone Marrow Cells; Diphosphonates; Female; Fibroblasts; Humans; Imidazoles; Infusions, Intravenous; Leukemia; Male; Middle Aged; Osteoporosis; Stem Cell Transplantation; Stem Cells; Transplantation, Homologous; Zoledronic Acid	2005
Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Annals of internal medicine, 2006, Feb-21, Volume: 144, Issue:4 Topics: Bone Density; Bone Density Conservation Agents; Chronic Disease; Diphosphonates; Double-Blind Method; Follow-Up Studies; Humans; Hydroxycholecalciferols; Hyperparathyroidism, Secondary; Hypocalcemia; Imidazoles; Infusions, Intravenous; Liver Failure; Liver Transplantation; Osteoporosis; Parathyroid Hormone; Zoledronic Acid	2006
Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Annals of hematology, 2006, Volume: 85, Issue:9 Topics: Adolescent; Adult; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Male; Osteogenesis; Osteoporosis; Prospective Studies; Thalassemia; Zoledronic Acid	2006
Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica, 2006, Volume: 91, Issue:9 Topics: beta-Thalassemia; Bone Density; Bone Resorption; Diphosphonates; Humans; Imidazoles; Osteoporosis; Placebos; Treatment Outcome; Zoledronic Acid	2006
Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Annals of hematology, 2007, Volume: 86, Issue:1 Topics: Adult; beta-Thalassemia; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Insulin-Like Growth Factor I; Male; Osteocalcin; Osteoporosis; Osteoprotegerin; Peptides; Treatment Outcome; Zoledronic Acid	2007
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-20, Volume: 25, Issue:9 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Boston; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Time Factors; Treatment Outcome; Zoledronic Acid	2007
Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study. International journal of urology : official journal of the Japanese Urological Association, 2007, Volume: 14, Issue:4 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Orchiectomy; Osteoporosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Zoledronic Acid	2007
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU international, 2007, Volume: 100, Issue:1 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Diphosphonates; Double-Blind Method; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome; Zoledronic Acid	2007
The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clinical genitourinary cancer, 2007, Volume: 5, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Placebos; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2007
Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). International journal of laboratory hematology, 2007, Volume: 29, Issue:5 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Osteoporosis; Paraproteinemias; Zoledronic Acid	2007
Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis. Acta haematologica, 2008, Volume: 119, Issue:1 Topics: Adult; Bone Density; Bone Density Conservation Agents; Diphosphonates; Erythropoiesis; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Thalassemia; Zoledronic Acid	2008

Other Studies

293 other study(ies) available for zoledronic acid and Age-Related Osteoporosis

Article	Year
Retrospective Study of the Effects of Zoledronic Acid on Muscle Mass in Osteoporosis Patients. Drug design, development and therapy, 2021, Volume: 15 Topics: Absorptiometry, Photon; Aged; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Cohort Studies; Female; Humans; Male; Middle Aged; Muscle, Skeletal; Osteoporosis; Retrospective Studies; Zoledronic Acid	2021
Cost-effectiveness of 3 versus 6 years of zoledronic acid treatment before bisphosphonate holiday for women with osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2022, Volume: 33, Issue:1 Topics: Bone Density Conservation Agents; Cost-Benefit Analysis; Diphosphonates; Female; Holidays; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Zoledronic Acid	2022
Evaluation of estimated glomerular function (eGFR) versus creatinine clearance (CrCl) to predict acute kidney injury when using zoledronate for the treatment of osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2022, Volume: 33, Issue:3 Topics: Acute Kidney Injury; Creatinine; Glomerular Filtration Rate; Humans; Osteoporosis; Zoledronic Acid	2022
Tolerability of the first infusion of once-yearly zoledronic acid within one to two weeks after hip fracture surgery. Bone, 2022, Volume: 155 Topics: Aged, 80 and over; Antipyretics; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Hypocalcemia; Imidazoles; Male; Osteoporosis; Vitamin D; Zoledronic Acid	2022
The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2022, Volume: 33, Issue:6 Topics: Aged; Alendronate; Biomarkers; Bone Density; Denosumab; Female; Humans; Male; Osteoporosis; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid	2022
Use of zoledronic acid in antiosteoporosis treatment is associated with a decreased blood lipid level in postmenopausal women with osteoporosis: a cohort study in China. Postgraduate medicine, 2022, Volume: 134, Issue:4 Topics: Atorvastatin; Bone Density Conservation Agents; Cholesterol, LDL; Cohort Studies; Female; Humans; Lipids; Osteoporosis; Postmenopause; Zoledronic Acid	2022
Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS). Journal of Korean medical science, 2022, Apr-04, Volume: 37, Issue:13 Topics: Bone Density; Cancellous Bone; Denosumab; Female; Humans; Osteoporosis; Postmenopause; Retrospective Studies; Zoledronic Acid	2022
Additive Effect of Parathyroid Hormone and Zoledronate Acid on Prevention Particle Wears-Induced Implant Loosening by Promoting Periprosthetic Bone Architecture and Strength in an Ovariectomized Rat Model. Frontiers in endocrinology, 2022, Volume: 13 Topics: Animals; Bone Density Conservation Agents; Humans; Osteolysis; Osteoporosis; Parathyroid Hormone; Rats; Zoledronic Acid	2022
The Impact of Various Anti-Osteoporosis Drugs on All-Cause Mortality After Hip Fractures: A Nationwide Population Study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2022, Volume: 37, Issue:8 Topics: Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Hip Fractures; Humans; Osteoporosis; Osteoporotic Fractures; Zoledronic Acid	2022
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2022, Volume: 28, Issue:10 Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Teriparatide; United States; Zoledronic Acid	2022
Renal safety of zoledronic acid for osteoporosis in adults 75 years and older. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2022, Volume: 33, Issue:11 Topics: Acute Kidney Injury; Aged; Creatinine; Cross-Sectional Studies; Glomerular Filtration Rate; Humans; Kidney; Osteoporosis; Retrospective Studies; Zoledronic Acid	2022
Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan. Archives of osteoporosis, 2022, 07-15, Volume: 17, Issue:1 Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Female; Humans; Ibandronic Acid; Male; Medication Adherence; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Taiwan; Teriparatide; Zoledronic Acid	2022
Genetic Polymorphisms of Nuclear Factor-κB Family Affect the Bone Mineral Density Response to Zoledronic Acid Therapy in Postmenopausal Chinese Women. Genes, 2022, 07-27, Volume: 13, Issue:8 Topics: Bone Density; China; Female; Humans; NF-kappa B; Osteoporosis; Polymorphism, Single Nucleotide; Postmenopause; Zoledronic Acid	2022
Real-world effectiveness of osteoporosis treatments in Germany. Archives of osteoporosis, 2022, 08-31, Volume: 17, Issue:1 Topics: Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Fractures, Bone; Germany; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Zoledronic Acid	2022
Cost-effectiveness analysis of five drugs for treating postmenopausal women in the United States with osteoporosis and a very high fracture risk. Journal of endocrinological investigation, 2023, Volume: 46, Issue:2 Topics: Bone Density Conservation Agents; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Denosumab; Female; Hip Fractures; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Teriparatide; United States; Zoledronic Acid	2023
Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates. The Journal of clinical endocrinology and metabolism, 2022, 12-17, Volume: 108, Issue:1 Topics: Bone Density Conservation Agents; Follow-Up Studies; Humans; Inpatients; Orthopedics; Osteoporosis; Osteoporotic Fractures; Secondary Prevention; Zoledronic Acid	2022
Drug-Inclusive Inorganic-Organic Hybrid Systems for the Controlled Release of the Osteoporosis Drug Zoledronate. Molecules (Basel, Switzerland), 2022, Sep-21, Volume: 27, Issue:19 Topics: Bone Density Conservation Agents; Calcium; Delayed-Action Preparations; Diphosphonates; Durapatite; Humans; Imidazoles; Osteoporosis; Zoledronic Acid	2022
Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study. The Journal of clinical endocrinology and metabolism, 2023, 03-10, Volume: 108, Issue:4 Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Female; Humans; Male; Osteoporosis; Osteoporotic Fractures; Zoledronic Acid	2023
Intracardiac thrombosis following intravenous zoledronate treatment in a child with steroid-induced osteoporosis. Journal of pediatric endocrinology & metabolism : JPEM, 2023, Mar-28, Volume: 36, Issue:3 Topics: Bone Density Conservation Agents; Child; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Osteoporosis; Steroids; Thrombosis; Zoledronic Acid	2023
Release of drugs used in the treatment of osteoporosis from zeolites with divalent ions-Influence of the type of ion and drug on the release profile. Journal of biomedical materials research. Part B, Applied biomaterials, 2023, Volume: 111, Issue:5 Topics: Calcium; Humans; Magnesium; Osteoporosis; Pharmaceutical Preparations; Risedronic Acid; Zeolites; Zinc; Zoledronic Acid	2023
Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study. Bone, 2023, Volume: 168 Topics: Alendronate; Bone Density Conservation Agents; Coronary Artery Disease; Diphosphonates; DNA-Binding Proteins; Humans; Osteoporosis; Pharmacovigilance; Teriparatide; Zoledronic Acid	2023
Beneficial effects of the fructus Acta pharmaceutica (Zagreb, Croatia), 2022, Jun-01, Volume: 72, Issue:2 Topics: Animals; Bone and Bones; Osteoporosis; Plant Extracts; Rabbits; Zoledronic Acid	2022
Does resveratrol favor peri-implant bone repair in rats with ovariectomy-induced osteoporosis? Gene expression, counter-torque and micro-CT analysis. Brazilian oral research, 2023, Volume: 37 Topics: Animals; Bone Density; Female; Osteoporosis; Ovariectomy; Rats; Resveratrol; Torque; X-Ray Microtomography; Zoledronic Acid	2023
Bone Microarchitecture and Strength Changes During Teriparatide and Zoledronic Acid Treatment in a Patient with Pregnancy and Lactation-Associated Osteoporosis with Multiple Vertebral Fractures. Calcified tissue international, 2023, Volume: 112, Issue:5 Topics: Adult; Bone Density; Bone Density Conservation Agents; Female; Humans; Lactation; Osteoporosis; Pregnancy; Teriparatide; Zoledronic Acid	2023
Real-World Management of Patients With Osteoporosis at Very High Risk of Fracture. The Journal of the American Academy of Orthopaedic Surgeons, 2023, Mar-15, Volume: 31, Issue:6 Topics: Aged; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Male; Medicare; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; United States; Zoledronic Acid	2023
The nanoformula of zoledronic acid and calcium carbonate targets osteoclasts and reverses osteoporosis. Biomaterials, 2023, Volume: 296 Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Calcium Carbonate; Mice; Osteoclasts; Osteoporosis; Zoledronic Acid	2023
Safety and effectiveness of once-yearly zoledronic acid in Japanese osteoporosis patients: three-year post-marketing surveillance. Journal of bone and mineral metabolism, 2023, Volume: 41, Issue:2 Topics: Aged; Bone Density; Bone Density Conservation Agents; COVID-19; Diphosphonates; East Asian People; Humans; Imidazoles; Male; Osteoporosis; Pandemics; Product Surveillance, Postmarketing; Prospective Studies; Zoledronic Acid	2023
Letter to the Editor From Riahi and Gruntmanis: "Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates". The Journal of clinical endocrinology and metabolism, 2023, 08-18, Volume: 108, Issue:9 Topics: Humans; Inpatients; Osteoporosis; Osteoporotic Fractures; Zoledronic Acid	2023
Response to Letter to the Editor From Riahi and Gruntmanis: "Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates". The Journal of clinical endocrinology and metabolism, 2023, 08-18, Volume: 108, Issue:9 Topics: Fractures, Bone; Humans; Inpatients; Osteoporosis; Zoledronic Acid	2023
A Bone-Penetrating Precise Controllable Drug Release System Enables Localized Treatment of Osteoporotic Fracture Prevention via Modulating Osteoblast-Osteoclast Communication. Small (Weinheim an der Bergstrasse, Germany), 2023, Volume: 19, Issue:26 Topics: Animals; Bone and Bones; Drug Liberation; Female; Osteoblasts; Osteoclasts; Osteoporosis; Osteoporotic Fractures; Rats; Zoledronic Acid	2023
Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2023, Volume: 38, Issue:6 Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Medicare; Osteoporosis; Osteoporosis, Postmenopausal; Retrospective Studies; United States; Zoledronic Acid	2023
Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter. Journal of the Formosan Medical Association = Taiwan yi zhi, 2023, Volume: 122 Suppl 1 Topics: Bone Density Conservation Agents; Humans; Osteoporosis; Osteoporotic Fractures; Spinal Fractures; Zoledronic Acid	2023
[Side effects of osteoporosis treatments: how to explain them to patients?] Revue medicale suisse, 2023, Apr-19, Volume: 19, Issue:823 Topics: Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Teriparatide; Zoledronic Acid	2023
Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database. Joint bone spine, 2023, Volume: 90, Issue:6 Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Incidence; Osteoporosis; Pharmacovigilance; Risedronic Acid; Risk Factors; Zoledronic Acid	2023
The real-world adherence of the first-line anti-osteoporosis medications in Taiwan: Visualize the gap between reality and expectations. Journal of the Formosan Medical Association = Taiwan yi zhi, 2023, Volume: 122 Suppl 1 Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Humans; Medication Adherence; Motivation; Osteoporosis; Retrospective Studies; Taiwan; Zoledronic Acid	2023
Zoledronic acid-induced severe lymphopenia. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2023, Volume: 34, Issue:9 Topics: Acute-Phase Reaction; Anemia; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Lymphopenia; Male; Osteoporosis; Thrombocytopenia; Zoledronic Acid	2023
Zoledronate Promotes Peri-Implant Osteogenesis in Diabetic Osteoporosis by the AMPK Pathway. Calcified tissue international, 2023, Volume: 113, Issue:3 Topics: AMP-Activated Protein Kinases; Animals; Cell Differentiation; Diabetes Mellitus; Glucose; Osteoblasts; Osteogenesis; Osteoporosis; Rats; X-Ray Microtomography; Zoledronic Acid	2023
Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study. Endocrine, 2023, Volume: 82, Issue:1 Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Retrospective Studies; Teriparatide; Zoledronic Acid	2023
Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis. Archives of osteoporosis, 2023, 07-17, Volume: 18, Issue:1 Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Denosumab; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postmenopause; Quality-Adjusted Life Years; Teriparatide; Zoledronic Acid	2023
The effect of pharmacological treatment in combination with vitamin K on healing in an experimental rat model of osteoporosis. Joint diseases and related surgery, 2023, Apr-27, Volume: 34, Issue:2 Topics: Animals; Bone Density Conservation Agents; Female; Fracture Healing; Osteoporosis; Osteoporotic Fractures; Rats; Rats, Sprague-Dawley; Teriparatide; Vitamin K; Zoledronic Acid	2023
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2023, Volume: 34, Issue:11 Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Registries; Spinal Fractures; Zoledronic Acid	2023
Zoledronic acid epigenetically alleviates high-glucose-suppressed osteogenic differentiation of MC3T3-E1 cells. European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:16 Topics: Bone Resorption; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Epigenesis, Genetic; Glucose; Humans; MicroRNAs; Osteogenesis; Osteoporosis; RNA, Long Noncoding; Zoledronic Acid	2023
Clinicians' views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study. BMC musculoskeletal disorders, 2023, Sep-29, Volume: 24, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid	2023
Prediction of musculoskeletal pain after the first intravenous zoledronic acid injection in patients with primary osteoporosis: development and evaluation of a new nomogram. BMC musculoskeletal disorders, 2023, Oct-25, Volume: 24, Issue:1 Topics: Adolescent; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Humans; Musculoskeletal Pain; Nomograms; Osteoporosis; Vitamin D; Zoledronic Acid	2023
Risk factors for new vertebral compression fracture after vertebroplasty and efficacy of osteoporosis treatment: A STROBE-compliant retrospective study. Medicine, 2023, Nov-24, Volume: 102, Issue:47 Topics: Bone Cements; Fractures, Compression; Humans; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; Risk Factors; Spinal Fractures; Steroids; Treatment Outcome; Vertebroplasty; Zoledronic Acid	2023
Zoledronic acid is effective and safe in migratory osteoporosis. Rheumatology (Oxford, England), 2020, 02-01, Volume: 59, Issue:2 Topics: Adult; Aged; Bone Density Conservation Agents; Female; Humans; Male; Middle Aged; Osteoporosis; Treatment Outcome; Zoledronic Acid	2020
Review: Long-term alendronate or zoledronic acid reduces fractures in postmenopausal women with osteoporosis. Annals of internal medicine, 2019, 08-20, Volume: 171, Issue:4 Topics: Alendronate; Female; Holidays; Humans; Osteoporosis; Postmenopause; Zoledronic Acid	2019
Efficiency of Zoledronic Acid in Inhibiting Accelerated Periprosthetic Bone Loss After Cementless Total Hip Arthroplasty in Osteoporotic Patients: A Prospective, Cohort Study. Orthopaedic surgery, 2019, Volume: 11, Issue:4 Topics: Adult; Aged; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Disease Progression; Female; Humans; Male; Middle Aged; Osteoporosis; Prospective Studies; Vitamin D; Zoledronic Acid	2019
Nanohydroxyapatite Based Ceramic Carrier Promotes Bone Formation in a Femoral Neck Canal Defect in Osteoporotic Rats. Biomacromolecules, 2020, 02-10, Volume: 21, Issue:2 Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Regeneration; Bone Resorption; Calcium Sulfate; Drug Carriers; Exosomes; Female; Femur Neck; Hip Fractures; Hydroxyapatites; Nanostructures; Osteogenesis; Osteoporosis; Rats, Sprague-Dawley; Recombinant Proteins; Transforming Growth Factor beta; X-Ray Microtomography; Zoledronic Acid	2020
Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy. BMC musculoskeletal disorders, 2019, Nov-06, Volume: 20, Issue:1 Topics: Absorptiometry, Photon; Adipose Tissue; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Marrow; Breast Neoplasms; Cancellous Bone; Female; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Lumbar Vertebrae; Magnetic Resonance Imaging; Middle Aged; Osteoporosis; Postmenopause; Zoledronic Acid	2019
Zoledronic acid in nine patients with transient osteoporosis of the hip. Clinical rheumatology, 2020, Volume: 39, Issue:1 Topics: Adult; Bone Density; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid	2020
Therapeutic effect of percutaneous kyphoplasty combined with anti-osteoporosis drug on postmenopausal women with osteoporotic vertebral compression fracture and analysis of postoperative bone cement leakage risk factors: a retrospective cohort study. Journal of orthopaedic surgery and research, 2019, Dec-18, Volume: 14, Issue:1 Topics: Bone Cements; Bone Density Conservation Agents; Cohort Studies; Combined Modality Therapy; Female; Fractures, Compression; Humans; Kyphoplasty; Middle Aged; Osteoporosis; Osteoporotic Fractures; Postmenopause; Postoperative Complications; Retrospective Studies; Risk Assessment; Risk Factors; Spinal Fractures; Zoledronic Acid	2019
Risk of Cataract Surgery and Age-Related Macular Degeneration After Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A Multi-Database Cohort Study. Drugs & aging, 2020, Volume: 37, Issue:4 Topics: Aged; Bone Density Conservation Agents; Cataract Extraction; Cohort Studies; Databases, Factual; Denosumab; Female; Humans; Macular Degeneration; Male; Middle Aged; Osteoporosis; Risk; Zoledronic Acid	2020
Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries. Bone, 2020, Volume: 134 Topics: Bone Density Conservation Agents; Cohort Studies; Denmark; Humans; Osteoporosis; Registries; Risk Factors; Sweden; Zoledronic Acid	2020
Zoledronic acid accelerates osteogenesis of bone marrow mesenchymal stem cells by attenuating oxidative stress via the SIRT3/SOD2 pathway and thus alleviates osteoporosis. European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:4 Topics: Cells, Cultured; Dose-Response Relationship, Drug; Humans; Hydrogen Peroxide; Mesenchymal Stem Cells; Osteogenesis; Osteoporosis; Oxidative Stress; Sirtuin 3; Structure-Activity Relationship; Superoxide Dismutase; Zoledronic Acid	2020
Long-Term Response to a Bioactive Biphasic Biomaterial in the Femoral Neck of Osteoporotic Rats. Tissue engineering. Part A, 2020, Volume: 26, Issue:19-20 Topics: Animals; Biocompatible Materials; Bone Morphogenetic Protein 2; Calcium Sulfate; Durapatite; Femur Neck; Humans; Osteoporosis; Rats; Recombinant Proteins; Tissue Engineering; Zoledronic Acid	2020
Modulation of bone formation and resorption using a novel zoledronic acid loaded gelatin nanoparticles integrated porous titanium scaffold: an in vitro and in vivo study. Biomedical materials (Bristol, England), 2020, 07-27, Volume: 15, Issue:5 Topics: Animals; Biocompatible Materials; Bone and Bones; Bone Regeneration; Bone Resorption; Cell Adhesion; Cell Differentiation; Cell Proliferation; Female; Gelatin; In Vitro Techniques; Nanoparticles; Osteoclasts; Osteogenesis; Osteoporosis; Porosity; Rabbits; Static Electricity; Tissue Scaffolds; Titanium; Zoledronic Acid	2020
Adherence to and persistence with zoledronic acid treatment for osteoporosis-reasons for early discontinuation. Archives of osteoporosis, 2020, 04-17, Volume: 15, Issue:1 Topics: Aged; Bone Density Conservation Agents; Female; Humans; Male; Medication Adherence; Middle Aged; Osteoporosis; Retrospective Studies; Sweden; Time Factors; Withholding Treatment; Zoledronic Acid	2020
Zoledronate. Bone, 2020, Volume: 137 Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteitis Deformans; Osteoporosis; Zoledronic Acid	2020
Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2020, Volume: 31, Issue:9 Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Zoledronic Acid	2020
Synergistic effect of graphene oxide and zoledronic acid for osteoporosis and cancer treatment. Scientific reports, 2020, 05-08, Volume: 10, Issue:1 Topics: Breast Neoplasms; Cell Differentiation; Cell Proliferation; Cell Survival; Female; Graphite; Humans; MCF-7 Cells; Nanostructures; Neoplasm Metastasis; Osteoporosis; Zoledronic Acid	2020
Alendronate or Zoledronic acid do not impair wound healing after tooth extraction in postmenopausal women with osteoporosis. Bone, 2020, Volume: 137 Topics: Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Tooth Extraction; Wound Healing; Zoledronic Acid	2020
Transient Osteoporosis of the Hip Mimicking Flare of Psoriatic Arthritis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2020, Volume: 26, Issue:4 Topics: Aged; Arthritis, Psoriatic; Bone Density Conservation Agents; Bone Marrow; Bone Remodeling; Diagnosis, Differential; Edema; Femur Head; Humans; Magnetic Resonance Imaging; Male; Osteoporosis; Symptom Flare Up; Zoledronic Acid	2020
Effect of different hydration doses on renal function in patients with primary osteoporosis treated with zoledronic acid: A hospital-based retrospective cohort study. Medicine, 2020, Jun-19, Volume: 99, Issue:25 Topics: Aged; Bone Density Conservation Agents; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Osteoporosis; Rehydration Solutions; Retrospective Studies; Zoledronic Acid	2020
Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment. Journal of bone and mineral metabolism, 2020, Volume: 38, Issue:6 Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Denosumab; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Retrospective Studies; Tartrate-Resistant Acid Phosphatase; Withholding Treatment; Zoledronic Acid	2020
Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2021, Volume: 32, Issue:3 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Cohort Studies; Denosumab; Female; Frail Elderly; Humans; Male; Medicare; Osteoporosis; Retrospective Studies; Teriparatide; United States; Zoledronic Acid	2021
Bisphosphonate-induced Posterior Scleritis. Ophthalmology, 2021, Volume: 128, Issue:3 Topics: Bone Density Conservation Agents; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Osteoporosis; Posterior Eye Segment; Scleritis; Zoledronic Acid	2021
A Single-Center Prospective Study of 116 Women with Osteoporosis Treated with Zoledronic Acid Monitored by Electrocardiography for the Development of Cardiac Arrhythmia During the Acute Phase in China. Medical science monitor : international medical journal of experimental and clinical research, 2021, Mar-12, Volume: 27 Topics: Acute Disease; Aged; Arrhythmias, Cardiac; Asian People; Atrial Fibrillation; Diphosphonates; Electrocardiography; Female; Heart Atria; Heart Rate; Humans; Middle Aged; Monitoring, Physiologic; Osteoporosis; Prospective Studies; Zoledronic Acid	2021
Effect of zoledronic acid on bone nanocomposites organization and prevention of bone mineral density loss in ovariectomized rats. Drug metabolism and personalized therapy, 2021, 03-29, Volume: 36, Issue:3 Topics: Animals; Bone Density; Diphosphonates; Female; Humans; Nanocomposites; Osteoporosis; Rats; Zoledronic Acid	2021
The effect of high concentration of zoledronic acid on tooth induced movement and its repercussion on root, periodontal ligament and alveolar bone tissues in rats. Scientific reports, 2021, 04-07, Volume: 11, Issue:1 Topics: Alveolar Process; Animals; Bone Density Conservation Agents; Bone Resorption; Drug Evaluation, Preclinical; Male; Osteoporosis; Periodontal Ligament; Rats, Wistar; Tooth Movement Techniques; Tooth Root; Zoledronic Acid	2021
Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis. BMC cancer, 2021, Apr-17, Volume: 21, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Comorbidity; Drug Administration Schedule; Humans; Japan; Kidney Function Tests; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Public Health Surveillance; Retrospective Studies; Risk Factors; Spinal Fractures; Zoledronic Acid	2021
Zoledronic acid modulates osteoclast apoptosis through activation of the NF-κB signaling pathway in ovariectomized rats. Experimental biology and medicine (Maywood, N.J.), 2021, Volume: 246, Issue:15 Topics: Animals; Apoptosis; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Cell Differentiation; Female; NF-kappa B; Osteoclasts; Osteogenesis; Osteoporosis; Ovariectomy; Rats, Sprague-Dawley; Signal Transduction; Zoledronic Acid	2021
Early adverse events after the first administration of zoledronic acid in Japanese patients with osteoporosis. Journal of bone and mineral metabolism, 2021, Volume: 39, Issue:5 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Japan; Osteoporosis; Zoledronic Acid	2021
Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia? Clinical rheumatology, 2021, Volume: 40, Issue:10 Topics: Bone Density; Bone Density Conservation Agents; Denosumab; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Sarcopenia; Zoledronic Acid	2021
Acute Tubular Necrosis Caused by Zoledronic Acid Infusion in a Patient With Osteoporosis. American journal of therapeutics, 2021, 04-29, Volume: 29, Issue:1 Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Infusions, Intravenous; Necrosis; Osteoporosis; Zoledronic Acid	2021
Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020. Journal of general internal medicine, 2022, Volume: 37, Issue:8 Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denosumab; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Zoledronic Acid	2022
Drug-induced hepatotoxicity linked to zoledronic acid in the treatment of an elderly man with primary osteoporosis. International journal of clinical pharmacology and therapeutics, 2021, Volume: 59, Issue:11 Topics: Aged; Bone Density Conservation Agents; Chemical and Drug Induced Liver Injury; Diphosphonates; Humans; Male; Osteoporosis; Pharmaceutical Preparations; Zoledronic Acid	2021
Inflammatory Markers and Frailty in Long-Term Care Residents. Journal of the American Geriatrics Society, 2017, Volume: 65, Issue:8 Topics: Activities of Daily Living; Aged; Biomarkers; Bone Density Conservation Agents; Cytokines; Diphosphonates; Female; Frail Elderly; Humans; Imidazoles; Inflammation; Long-Term Care; Osteoporosis; Zoledronic Acid	2017
Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study. British journal of clinical pharmacology, 2017, Volume: 83, Issue:10 Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Calcium; Chemokine CCL2; Diphosphonates; Female; Fibroblast Growth Factor-23; Humans; Hyperparathyroidism, Secondary; Imidazoles; Infusions, Intravenous; Interleukin-18; Male; Osteoporosis; Pilot Projects; Renal Elimination; Zoledronic Acid	2017
Histomorphometric changes following treatment for osteoporosis. Journal of endocrinological investigation, 2017, Volume: 40, Issue:9 Topics: Anabolic Agents; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clinical Trials as Topic; Humans; Osteoporosis; Teriparatide; Thiophenes; Treatment Outcome; Zoledronic Acid	2017
A novel large fragment deletion in PLS3 causes rare X-linked early-onset osteoporosis and response to zoledronic acid. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2017, Volume: 28, Issue:9 Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Diphosphonates; Gene Deletion; Genetic Diseases, X-Linked; Humans; Imidazoles; Male; Membrane Glycoproteins; Microfilament Proteins; Osteoporosis; Pedigree; Phenotype; Radiography; Zoledronic Acid	2017
Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism. Endocrinology, 2017, 09-01, Volume: 158, Issue:9 Topics: Animals; Bone and Bones; Bone Resorption; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Imidazoles; Mice; Mice, Knockout; Nuclear Matrix-Associated Proteins; Osteoporosis; Parathyroid Hormone; Raloxifene Hydrochloride; Transcription Factors; Zoledronic Acid	2017
Bilateral Acute Anterior Uveitis and Conjunctivitis following Intravenous Zoledronic Acid. The Journal of the Association of Physicians of India, 2017, Volume: 65, Issue:7 Topics: Aged; Bone Density Conservation Agents; Conjunctivitis; Diphosphonates; Humans; Imidazoles; Male; Osteoporosis; Uveitis, Anterior; Zoledronic Acid	2017
Effect of zoledronic acid on lumbar spinal fusion in osteoporotic patients. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2017, Volume: 26, Issue:11 Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Lumbar Vertebrae; Osteoporosis; Retrospective Studies; Spinal Fusion; Zoledronic Acid	2017
Efficacy and treatment costs of zoledronate versus pamidronate in paediatric osteoporosis. Archives of disease in childhood, 2018, Volume: 103, Issue:1 Topics: Administration, Intravenous; Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Female; Health Care Costs; Humans; Imidazoles; Male; Osteoporosis; Pamidronate; Retrospective Studies; Zoledronic Acid	2018
Assessment of geriatric predictors of adherence to Zoledronic acid treatment for osteoporosis: a prospective follow-up study. Acta clinica Belgica, 2018, Volume: 73, Issue:4 Topics: Aged; Aged, 80 and over; Body Height; Bone Density Conservation Agents; Depression; Female; Follow-Up Studies; Geriatric Assessment; Humans; Male; Medication Adherence; Osteoporosis; Prospective Studies; Risk Factors; Zoledronic Acid	2018
Bis‑enoxacin blocks alveolar bone resorption in rats with ovariectomy‑induced osteoporosis. Molecular medicine reports, 2018, Volume: 17, Issue:2 Topics: Alveolar Bone Loss; Animals; Body Weight; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Enoxacin; Female; Imidazoles; Microscopy, Fluorescence; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; X-Ray Microtomography; Zoledronic Acid	2018
Simple 3,4-Dihydroxy-L-Phenylalanine Surface Modification Enhances Titanium Implant Osseointegration in Ovariectomized Rats. Scientific reports, 2017, 12-19, Volume: 7, Issue:1 Topics: Animals; Bone Resorption; Bone-Anchored Prosthesis; Cell Differentiation; Coated Materials, Biocompatible; Dental Implantation, Endosseous; Dental Implants; Dental Prosthesis Design; Diphosphonates; Female; Osseointegration; Osteoclasts; Osteoporosis; Ovariectomy; Phenylalanine; Rats; Rats, Sprague-Dawley; Surface Properties; Titanium; Torque; X-Ray Microtomography; Zoledronic Acid	2017
[Influence of history of oral bisphosphonates on the incidence rate of fever after intravenous injection of zoledronic acid in patients with osteoporosis]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2016, Aug-18, Volume: 48, Issue:4 Topics: Absorptiometry, Photon; Administration, Oral; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fever; Humans; Imidazoles; Incidence; Injections, Intravenous; Osteoporosis; Prevalence; Zoledronic Acid	2016
The compositional and nano-structural basis of fracture healing in healthy and osteoporotic bone. Scientific reports, 2018, 01-25, Volume: 8, Issue:1 Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 7; Bony Callus; Diphosphonates; Disease Models, Animal; Fracture Healing; Fractures, Bone; Imidazoles; Osteoporosis; Rats; Scattering, Small Angle; Spectroscopy, Fourier Transform Infrared; Zoledronic Acid	2018
After the fall: improving osteoporosis treatment following hip fracture. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018, Volume: 29, Issue:6 Topics: Accidental Falls; Aged; Bone Density Conservation Agents; Denosumab; Drug Administration Schedule; Hip Fractures; Hospitalization; Humans; Osteoporosis; Osteoporotic Fractures; Quality Improvement; Retrospective Studies; Secondary Prevention; Standard of Care; Texas; Zoledronic Acid	2018
Prevention of ovariectomy-induced osteoporosis in rats : Comparative study of zoledronic acid, parathyroid hormone (1-34) and strontium ranelate. Zeitschrift fur Gerontologie und Geriatrie, 2019, Volume: 52, Issue:2 Topics: Animals; Bone Density Conservation Agents; Female; Osteoporosis; Ovariectomy; Parathyroid Hormone; Rats; Rats, Sprague-Dawley; Thiophenes; X-Ray Microtomography; Zoledronic Acid	2019
Effects of bone remodeling agents following teriparatide treatment. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018, Volume: 29, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Denosumab; Drug Administration Schedule; Drug Therapy, Combination; Female; Femur Neck; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; Teriparatide; Zoledronic Acid	2018
Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy. Medical archives (Sarajevo, Bosnia and Herzegovina), 2018, Volume: 72, Issue:3 Topics: Absorptiometry, Photon; Adult; beta-Thalassemia; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Femur Neck; Humans; Iran; Lumbar Vertebrae; Male; Osteoporosis; Retrospective Studies; Treatment Outcome; Zoledronic Acid	2018
Prior administration of vitamin K2 improves the therapeutic effects of zoledronic acid in ovariectomized rats by antagonizing zoledronic acid-induced inhibition of osteoblasts proliferation and mineralization. PloS one, 2018, Volume: 13, Issue:8 Topics: Animals; Animals, Newborn; Apoptosis; Bone Density; Bone Density Conservation Agents; Bone Development; Bone Morphogenetic Proteins; Calcium; Cell Proliferation; Cells, Cultured; Drug Antagonism; Female; Genetic Markers; Mice; Osteoblasts; Osteoporosis; Ovariectomy; Random Allocation; Rats, Wistar; Specific Pathogen-Free Organisms; Vitamin K 2; Zoledronic Acid	2018
Cost-effectiveness of single-dose zoledronic acid for nursing home residents with osteoporosis in the USA. BMJ open, 2018, 09-04, Volume: 8, Issue:9 Topics: Aged, 80 and over; Bone Density Conservation Agents; Cost-Benefit Analysis; Female; Homes for the Aged; Humans; Male; Markov Chains; Models, Theoretical; Nursing Homes; Osteoporosis; Osteoporotic Fractures; Outcome Assessment, Health Care; Quality of Life; Quality-Adjusted Life Years; United States; Zoledronic Acid	2018
Clinically Relevant Doses of Sclerostin Antibody Do Not Induce Osteonecrosis of the Jaw (ONJ) in Rats with Experimental Periodontitis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2019, Volume: 34, Issue:1 Topics: Animals; Antibodies; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Morphogenetic Proteins; Female; Genetic Markers; Osteoporosis; Ovariectomy; Periodontitis; Rats; Rats, Sprague-Dawley; Zoledronic Acid	2019
Annual Injection of Zoledronic Acid Improves Bone Status in Children with Cerebral Palsy and Rett Syndrome. Calcified tissue international, 2019, Volume: 104, Issue:4 Topics: Adolescent; Bone and Bones; Bone Density; Bone Density Conservation Agents; Cerebral Palsy; Child; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Rett Syndrome; Time Factors; Zoledronic Acid	2019
Circulating microRNA Panel as a Novel Biomarker to Diagnose Bisphosphonate-Related Osteonecrosis of the Jaw. International journal of medical sciences, 2018, Volume: 15, Issue:14 Topics: Animals; Biomarkers; Bisphosphonate-Associated Osteonecrosis of the Jaw; Circulating MicroRNA; Disease Models, Animal; Female; Humans; Oligonucleotide Array Sequence Analysis; Osteoporosis; Predictive Value of Tests; Prognosis; Rats; Rats, Sprague-Dawley; Zoledronic Acid	2018
To withhold or to implement bisphosphonate after cementless hip arthroplasty: a dilemma in elderly hip fracture patients. Journal of orthopaedic surgery and research, 2019, Feb-26, Volume: 14, Issue:1 Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Hip Prosthesis; Humans; Male; Osteoporosis; Retrospective Studies; Withholding Treatment; Zoledronic Acid	2019
Mesoporous bioactive glass/ɛ-polycaprolactone scaffolds promote bone regeneration in osteoporotic sheep. Acta biomaterialia, 2019, Volume: 90 Topics: Animals; Bone Regeneration; Disease Models, Animal; Drug Implants; Female; Glass; Humans; Mice; Osteoblasts; Osteoclasts; Osteogenesis; Osteoporosis; Polyesters; Porosity; RAW 264.7 Cells; Sheep; Zoledronic Acid	2019
Systemic sclerostin antibody treatment increases osseointegration and biomechanical competence of zoledronic-acid-coated dental implants in a rat osteoporosis model. European cells & materials, 2019, 05-17, Volume: 37 Topics: Animals; Antibodies; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Coated Materials, Biocompatible; Dental Implants; Disease Models, Animal; Female; Genetic Markers; Osseointegration; Osteoporosis; Rats; Rats, Wistar; Zoledronic Acid	2019
Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration. Urologia internationalis, 2013, Volume: 90, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Diseases; Denosumab; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Life Expectancy; Male; Numbers Needed To Treat; Osteoporosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Spinal Fractures; Time Factors; Treatment Outcome; Zoledronic Acid	2013
Orbital inflammation after zoledronate infusion: an emerging complication. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2013, Volume: 48, Issue:1 Topics: Aged; Blepharoptosis; Bone Density Conservation Agents; Diphosphonates; Edema; Exophthalmos; Eyelid Diseases; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Male; Methylprednisolone; Orbital Cellulitis; Osteoporosis; Tomography, X-Ray Computed; Zoledronic Acid	2013
The effect of bone morphometric changes on orthodontic tooth movement in an osteoporotic animal model. The Angle orthodontist, 2013, Volume: 83, Issue:5 Topics: Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Osteoporosis; Ovariectomy; Rats; Rats, Wistar; Tibia; Tooth Movement Techniques; X-Ray Microtomography; Zoledronic Acid	2013
Variation in the days supply field for osteoporosis medications in Ontario. Archives of osteoporosis, 2013, Volume: 8 Topics: Bone Density Conservation Agents; Diphosphonates; Drug Prescriptions; Drug Utilization; Humans; Imidazoles; Ontario; Osteoporosis; Zoledronic Acid	2013
Early healing of hydroxyapatite-coated implants in grafted bone of zoledronic acid-treated osteoporotic rabbits. Journal of periodontology, 2014, Volume: 85, Issue:2 Topics: Absorptiometry, Photon; Animals; Autografts; Bone Density; Bone Density Conservation Agents; Bone Transplantation; Calcification, Physiologic; Coated Materials, Biocompatible; Dental Implants; Diphosphonates; Durapatite; Female; Ilium; Imidazoles; Osseointegration; Osteoporosis; Ovariectomy; Rabbits; Stress, Mechanical; Tibia; Time Factors; Torque; Transplant Donor Site; Wound Healing; X-Ray Microtomography; Zoledronic Acid	2014
Primary health care nurses take on new challenges. Nursing New Zealand (Wellington, N.Z. : 1995), 2013, Volume: 19, Issue:3 Topics: Administration, Intravenous; Bone Density Conservation Agents; Clinical Competence; Diphosphonates; Humans; Imidazoles; New Zealand; Nurse's Role; Organizational Innovation; Osteoporosis; Primary Health Care; State Medicine; Zoledronic Acid	2013
The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study. International journal of oral and maxillofacial surgery, 2013, Volume: 42, Issue:11 Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Jaw Diseases; Mandible; Osteogenesis; Osteoporosis; Parathyroid Hormone; Rats; Rats, Sprague-Dawley; Tooth Extraction; Zoledronic Acid	2013
Acute phase response after zoledronic acid is associated with long-term effects on white blood cells. Calcified tissue international, 2013, Volume: 93, Issue:3 Topics: Acute-Phase Reaction; Administration, Oral; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Eosinophils; Female; Humans; Imidazoles; Leukocyte Count; Leukocytes; Lymphocytes; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Time Factors; Zoledronic Acid	2013
Dental implant placement with bone augmentation in a patient who received intravenous bisphosphonate treatment for osteoporosis. Journal (Canadian Dental Association), 2013, Volume: 79 Topics: Alveolar Ridge Augmentation; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Contraindications; Decision Trees; Dental Abutments; Dental Implantation, Endosseous; Diphosphonates; Humans; Imidazoles; Incisor; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Risk Assessment; Zirconium; Zoledronic Acid	2013
The importance of informed consent. Journal (Canadian Dental Association), 2013, Volume: 79 Topics: Alveolar Ridge Augmentation; Bone Density Conservation Agents; Dental Implantation, Endosseous; Diphosphonates; Humans; Imidazoles; Male; Osteoporosis; Zoledronic Acid	2013
Osseointegration of biochemically modified implants in an osteoporosis rodent model. European cells & materials, 2013, Jul-08, Volume: 25 Topics: Animals; Biomechanical Phenomena; Diphosphonates; Disease Models, Animal; Female; Fluorescent Dyes; Imidazoles; Implants, Experimental; Osseointegration; Osteoporosis; Rats; Rats, Wistar; Simvastatin; X-Ray Microtomography; Zoledronic Acid	2013
Osteoprotective effect of propranolol in ovariectomized rats: a comparison with zoledronic acid and alfacalcidol. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2013, Volume: 18, Issue:5 Topics: Adrenergic beta-Antagonists; Animals; Bone Density Conservation Agents; Diphosphonates; Female; Hydroxycholecalciferols; Imidazoles; Osteoporosis; Ovariectomy; Propranolol; Rats; Rats, Wistar; Zoledronic Acid	2013
The effects of zoledronic acid on mandibular fracture healing in an osteoporotic model: a stereological study. The Journal of craniofacial surgery, 2013, Volume: 24, Issue:4 Topics: Animals; Bone Density Conservation Agents; Bone Plates; Diphosphonates; Disease Models, Animal; Female; Fracture Healing; Imidazoles; Mandible; Mandibular Fractures; Osteogenesis; Osteoporosis; Ovariectomy; Random Allocation; Rats; Rats, Sprague-Dawley; Time Factors; Zoledronic Acid	2013
[Use of zoledronic acid for lung cancer with bone metastases - a study on reossification of osteolytic bone metastases]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteoporosis; Quality of Life; Young Adult; Zoledronic Acid	2013
Pentoxifylline and tocopherol in the treatment of yearly zoledronic acid-related osteonecrosis of the jaw in a corticosteroid-induced osteoporosis. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2014, Volume: 72, Issue:2 Topics: Adrenal Cortex Hormones; Alendronate; Antioxidants; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Male; Middle Aged; Osteoporosis; Pentoxifylline; Tocopherols; Tooth Extraction; Zoledronic Acid	2014
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. The Bulletin of Tokyo Dental College, 2013, Volume: 54, Issue:2 Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Arthritis, Rheumatoid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diabetes Complications; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Parenteral; Japan; Male; Middle Aged; Oral Surgical Procedures; Osteoporosis; Prostatic Neoplasms; Risedronic Acid; Treatment Outcome; Wound Healing; Zoledronic Acid	2013
[Risk factors of acute-phase response following the first-dose administration of zoledronic acid in the treatment of osteoporosis]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2013, Volume: 44, Issue:4 Topics: Acid Phosphatase; Acute-Phase Reaction; Aged; Diphosphonates; Female; Humans; Imidazoles; Isoenzymes; Male; Middle Aged; Osteoporosis; Risk Factors; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid	2013
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis. Current medical research and opinion, 2014, Volume: 30, Issue:1 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Managed Care Programs; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Teriparatide; United States; Zoledronic Acid	2014
Sequential treatment with monofluorophosphate and zoledronic acid in osteoporotic rats. Climacteric : the journal of the International Menopause Society, 2014, Volume: 17, Issue:4 Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium, Dietary; Diphosphonates; Disease Models, Animal; Female; Fluorides; Imidazoles; Osteoporosis; Osteoporotic Fractures; Ovariectomy; Phosphates; Rats; Rats, Sprague-Dawley; Treatment Outcome; Zoledronic Acid	2014
Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective. Bone, 2014, Volume: 59 Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Incidence; Male; Markov Chains; Osteoporosis; Osteoporotic Fractures; Risk Factors; Sweden; Treatment Outcome; Zoledronic Acid	2014
The effect of zoledronic acid on the volume of the fusion-mass in lumbar spinal fusion. Clinics in orthopedic surgery, 2013, Volume: 5, Issue:4 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Pain Measurement; Pain, Postoperative; Quality of Life; Radiography; Retrospective Studies; Spinal Fusion; Spinal Stenosis; Treatment Outcome; Zoledronic Acid	2013
Giant cell arteritis with visual loss following zoledronic acid infusion. International journal of rheumatic diseases, 2014, Volume: 17, Issue:1 Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Giant Cell Arteritis; Glucocorticoids; Humans; Imidazoles; Infusions, Parenteral; Osteoporosis; Treatment Outcome; Vision Disorders; Vision, Ocular; Zoledronic Acid	2014
Vitamin D status and parathyroid hormone concentrations influence the skeletal response to zoledronate and denosumab. Calcified tissue international, 2014, Volume: 94, Issue:5 Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcifediol; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Male; Osteoporosis; Parathyroid Hormone; Retrospective Studies; Treatment Outcome; Zoledronic Acid	2014
Successful treatment of transient osteoporosis with intravenous zoledronate: a case report. International journal of rheumatic diseases, 2014, Volume: 17, Issue:7 Topics: Absorptiometry, Photon; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Knee Joint; Magnetic Resonance Imaging; Male; Osteoporosis; Treatment Outcome; Zoledronic Acid	2014
To treat osteoporosis, Denosumab appears more effective than Zoledronate. Denosumab has the advantage in building bone density, and has fewer side effects. DukeMedicine healthnews, 2014, Volume: 20, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Male; Osteoporosis; Zoledronic Acid	2014
Atrial fibrillation following intravenous zolendronic acid for osteoporosis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2014, Volume: 20, Issue:4 Topics: Administration, Intravenous; Aged; Aged, 80 and over; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Retrospective Studies; Zoledronic Acid	2014
Zoledronic acid infusion for lumbar interbody fusion in osteoporosis. The Journal of surgical research, 2014, Volume: 192, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Disability Evaluation; Female; Follow-Up Studies; Fractures, Compression; Humans; Imidazoles; Infusions, Intravenous; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Pedicle Screws; Retrospective Studies; Spinal Fractures; Spinal Fusion; Spondylolisthesis; Treatment Outcome; Zoledronic Acid	2014
Zoledronic acid in osteoporosis secondary to mastocytosis. The American journal of medicine, 2014, Volume: 127, Issue:11 Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Male; Mastocytosis, Systemic; Middle Aged; Osteoporosis; Peptides; Zoledronic Acid	2014
Evaluation of the prescription of osteoporosis treatment after a major osteoporotic fracture. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2014, Volume: 20, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcium; Dietary Supplements; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; France; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Prescriptions; Raloxifene Hydrochloride; Retrospective Studies; Thiophenes; Treatment Outcome; Vitamin D; Wrist Injuries; Zoledronic Acid	2014
[Acute anterior uveitis associated with the use zoledronic acid]. Medicina, 2014, Volume: 74, Issue:5 Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Uveitis, Anterior; Zoledronic Acid	2014
Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2015, Volume: 21, Issue:3 Topics: Aged; Bone Density; Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Male; Osteoporosis; Retrospective Studies; Surveys and Questionnaires; Zoledronic Acid	2015
Development, in vitro and in vivo characterization of zoledronic acid functionalized hydroxyapatite nanoparticle based formulation for treatment of osteoporosis in animal model. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2015, Jan-23, Volume: 66 Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Durapatite; Female; Imidazoles; Nanoparticles; Osteoporosis; Ovariectomy; Random Allocation; Rats; Zoledronic Acid	2015
Efficacy, effectiveness and side effects of medications used to prevent fractures. Journal of internal medicine, 2015, Volume: 277, Issue:6 Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid	2015
Sclerosis in bisphosphonate-related osteonecrosis of the jaws and its correlation with the clinical stages: study of 43 cases. The British journal of oral & maxillofacial surgery, 2015, Volume: 53, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Dental Fistula; Diphosphonates; Female; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Mandibular Diseases; Osteoporosis; Osteosclerosis; Pain Measurement; Periostitis; Tomography, X-Ray Computed; Tooth Extraction; Zoledronic Acid	2015
Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2015, Volume: 26, Issue:5 Topics: Aged; Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug Prescriptions; Drug Utilization; Female; Health Services Research; Humans; Imidazoles; Male; Ontario; Osteoporosis; Pharmacopoeias as Topic; Practice Patterns, Physicians'; Zoledronic Acid	2015
Bisphosphonate-related osteonecrosis of the jaw: awareness and level of knowledge of Lebanese physicians. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:9 Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Cross-Sectional Studies; Diphosphonates; Female; Health Knowledge, Attitudes, Practice; Humans; Imidazoles; Lebanon; Male; Middle Aged; Osteoporosis; Physicians; Surveys and Questionnaires; Zoledronic Acid	2015
Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab. Arthritis & rheumatology (Hoboken, N.J.), 2015, Volume: 67, Issue:6 Topics: Abatacept; Adalimumab; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Factors; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hospitalization; Humans; Imidazoles; Immunoconjugates; Infections; Infliximab; Male; Medicare; Middle Aged; Osteoporosis; Proportional Hazards Models; Risk Factors; United States; Zoledronic Acid	2015
Medication-related osteonecrosis of the jaws from once per year intravenous zoledronic acid (Reclast): report of 4 cases. Implant dentistry, 2015, Volume: 24, Issue:2 Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis; Zoledronic Acid	2015
Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction. Lupus, 2015, Volume: 24, Issue:4-5 Topics: Acute-Phase Reaction; Aged; Aged, 80 and over; Autoimmunity; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Th1 Cells; Vitamin D; Zoledronic Acid	2015
Cancellous bone healing around strontium-doped hydroxyapatite in osteoporotic rats previously treated with zoledronic acid. Journal of biomedical materials research. Part B, Applied biomaterials, 2016, Volume: 104, Issue:3 Topics: Animals; Cancellous Bone; Diphosphonates; Durapatite; Female; Femoral Fractures; Fracture Healing; Imidazoles; Osteoporosis; Rats; Rats, Sprague-Dawley; Strontium; Zoledronic Acid	2016
Effect of zoledronic acid on spinal fusion outcomes in an ovariectomized rat model of osteoporosis. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2015, Volume: 33, Issue:9 Topics: Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Lumbar Vertebrae; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Spinal Fusion; X-Ray Microtomography; Zoledronic Acid	2015
The inhibitory effect of zoledronate on early-stage osteoinduction by recombinant human bone morphogenetic protein 2 in an osteoporosis model. Growth factors (Chur, Switzerland), 2015, Volume: 33, Issue:3 Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Remodeling; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Osteogenesis; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Skull; Transforming Growth Factor beta; Wound Healing; X-Ray Microtomography; Zoledronic Acid	2015
Pregnancy and Lactation-Associated Osteoporosis: Bone Histomorphometric Analysis and Response to Treatment with Zoledronic Acid. Calcified tissue international, 2015, Volume: 97, Issue:4 Topics: Adult; Bone Density; Bone Density Conservation Agents; Breast Feeding; Diphosphonates; Female; Humans; Imidazoles; Lactation; Osteoporosis; Pregnancy; Pregnancy Complications; Zoledronic Acid	2015
Zoledronic acid-induced hepatotoxicity relieved after subsequent infusions in a Chinese woman with glucocorticoid-induced osteoporosis. European journal of medical research, 2015, Aug-22, Volume: 20 Topics: Bone Density Conservation Agents; Chemical and Drug Induced Liver Injury; China; Diphosphonates; Female; Glucocorticoids; Humans; Imidazoles; Osteoporosis; Zoledronic Acid	2015
Animal model for medication-related osteonecrosis of the jaw with precedent metabolic bone disease. Bone, 2015, Volume: 81 Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Osteoclasts; Osteoporosis; Ovariectomy; Random Allocation; Rats; Rats, Sprague-Dawley; Tooth; X-Ray Microtomography; Zoledronic Acid	2015
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:3 Topics: Adjuvants, Pharmaceutic; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis; Triazoles; Zoledronic Acid	2016
Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience. The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:11 Topics: Acute-Phase Reaction; Adolescent; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Diseases; Calcitriol; Calcium; Child; Child, Preschool; Diphosphonates; Female; Humans; Hypercalcemia; Hypocalcemia; Hypophosphatemia; Imidazoles; Infant; Male; Osteogenesis Imperfecta; Osteoporosis; Prospective Studies; Retrospective Studies; Risk Factors; Young Adult; Zoledronic Acid	2015
Zoledronic acid suppresses callus remodeling but enhances callus strength in an osteoporotic rat model of fracture healing. Bone, 2015, Volume: 81 Topics: Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Remodeling; Bony Callus; Diphosphonates; Female; Femoral Fractures; Fracture Healing; Imaging, Three-Dimensional; Imidazoles; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; X-Ray Microtomography; Zoledronic Acid	2015
Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis. Endocrine, metabolic & immune disorders drug targets, 2016, Volume: 16, Issue:1 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Cognitive Dysfunction; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Osteoporosis; Prospective Studies; Zoledronic Acid	2016
Oral delivery of zoledronic acid by non-covalent conjugation with lysine-deoxycholic acid: In vitro characterization and in vivo anti-osteoporotic efficacy in ovariectomized rats. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2016, Jan-20, Volume: 82 Topics: Administration, Oral; Animals; Bone Density; Bone Density Conservation Agents; Caco-2 Cells; Deoxycholic Acid; Diphosphonates; Female; Humans; Imidazoles; Intestinal Absorption; Lysine; Osteoporosis; Ovariectomy; Permeability; Rats, Sprague-Dawley; Tibia; Zoledronic Acid	2016
Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate. Saudi medical journal, 2015, Volume: 36, Issue:11 Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Zoledronic Acid	2015
Osteoporosis treatment with zoledronic acid in pediatric population at a university hospital in Western Saudi Arabia. A 13-year experience. Saudi medical journal, 2015, Volume: 36, Issue:11 Topics: Adolescent; Bone Density Conservation Agents; Child; Diphosphonates; Hospitals, University; Humans; Imidazoles; Osteoporosis; Retrospective Studies; Saudi Arabia; Zoledronic Acid	2015
The effect of bisphosphonate treatment on the biochemical and cellular events during bone remodelling in response to microinjury stimulation. European cells & materials, 2015, Nov-27, Volume: 30 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Imidazoles; Mice; Osteoblasts; Osteoclasts; Osteocytes; Osteogenesis; Osteoporosis; Zoledronic Acid	2015
Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases. Quintessence international (Berlin, Germany : 1985), 2016, Volume: 47, Issue:5 Topics: Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis; Radiography, Panoramic; Zoledronic Acid	2016
[Bone Remodelling in the Proximal Femur after Uncemented Total Hip Arthroplasty in Patients with Osteoporosis]. Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca, 2015, Volume: 82, Issue:6 Topics: Absorptiometry, Photon; Aged; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Femur; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Prospective Studies; Zoledronic Acid	2015
[Clinical significance of serum bone metabolic markers in diagnosis and monitoring of myeloma bone disease]. Zhonghua yi xue za zhi, 2015, Nov-10, Volume: 95, Issue:42 Topics: Acid Phosphatase; Biomarkers; Collagen Type I; Diphosphonates; Humans; Imidazoles; Isoenzymes; Multiple Myeloma; Osteoporosis; Procollagen; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid	2015
Spontaneously recovered severe thrombocytopaenia following zoledronic acid infusion for osteoporosis. BMJ case reports, 2016, Feb-03, Volume: 2016 Topics: Aged; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis; Platelet Count; Remission, Spontaneous; Thrombocytopenia; Zoledronic Acid	2016
Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways. Oncotarget, 2016, Mar-01, Volume: 7, Issue:9 Topics: Biological Transport; Bone Density Conservation Agents; Bone Neoplasms; Cadherins; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Movement; Cell Survival; Diphosphonates; Diterpenes; Epithelial-Mesenchymal Transition; Farnesol; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Neoplasm Invasiveness; Nuclear Proteins; Osteoporosis; Osteosarcoma; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prenylation; Proto-Oncogene Proteins pp60(c-src); rho-Associated Kinases; Snail Family Transcription Factors; Twist-Related Protein 1; Zoledronic Acid	2016
Correlation between zoledronic acid infusion and repeat vertebroplasty surgery in osteoporotic patients. Current medical research and opinion, 2016, Volume: 32, Issue:5 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Male; Osteoporosis; Reoperation; Retrospective Studies; Risk Factors; Sex Factors; Spinal Fractures; Taiwan; Vertebroplasty; Zoledronic Acid	2016
Histological and biomechanical effects of zoledronate on fracture healing in an osteoporotic rat tibia model. Eklem hastaliklari ve cerrahisi = Joint diseases & related surgery, 2016, Volume: 27, Issue:1 Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Regeneration; Bony Callus; Diphosphonates; Female; Fracture Healing; Imidazoles; Osteoporosis; Osteoporotic Fractures; Rats; Rats, Wistar; Tibia; Treatment Outcome; Vitamin D; Zoledronic Acid	2016
Atypical femoral fracture following zoledronic acid treatment. Eklem hastaliklari ve cerrahisi = Joint diseases & related surgery, 2016, Volume: 27, Issue:1 Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Female; Femoral Fractures; Fracture Fixation; Humans; Ibandronic Acid; Imidazoles; Magnetic Resonance Imaging; Osteoporosis; Treatment Outcome; Withholding Treatment; Zoledronic Acid	2016
Severe non-infective systemic inflammatory response syndrome, shock, and end-organ dysfunction after zoledronic acid administration in a child. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2016, Volume: 27, Issue:7 Topics: Bone Density Conservation Agents; Child; Diphosphonates; Humans; Imidazoles; Male; Osteoporosis; Systemic Inflammatory Response Syndrome; Zoledronic Acid	2016
Guided bone regeneration in osteoporotic conditions following treatment with zoledronic acid. Clinical oral implants research, 2017, Volume: 28, Issue:3 Topics: Animals; Bone Density Conservation Agents; Bone Regeneration; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Osteoporosis; Ovariectomy; Parietal Bone; Rats, Wistar; Zoledronic Acid	2017
Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern. Current drug safety, 2016, Volume: 11, Issue:3 Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Hypocalcemia; Hypophosphatemia; Imidazoles; Male; Osteoporosis; Zoledronic Acid	2016
[Severe therapy refractive osteoporosis : A rare differential diagnosis]. Zeitschrift fur Rheumatologie, 2016, Volume: 75, Issue:7 Topics: Adult; Anti-Inflammatory Agents; Bone Density Conservation Agents; Chronic Disease; Diagnosis, Differential; Diphosphonates; Female; Humans; Imidazoles; Male; Mastocytosis, Systemic; Middle Aged; Osteoporosis; Rare Diseases; Treatment Failure; Treatment Outcome; Zoledronic Acid	2016
[Bisphosphonate use and related pharmaceutical issues II]. Acta pharmaceutica Hungarica, 2016, Volume: 86, Issue:1 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid	2016
Effects of local delivery of BMP2, zoledronate and their combination on bone microarchitecture, biomechanics and bone turnover in osteoporotic rabbits. Scientific reports, 2016, 06-22, Volume: 6 Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Remodeling; Diphosphonates; Disease Models, Animal; Drug Delivery Systems; Female; Femur Neck; Fibrin Tissue Adhesive; Imidazoles; Osteoporosis; Ovariectomy; Rabbits; Recombinant Proteins; X-Ray Microtomography; Zoledronic Acid	2016
Effect of intravenous zoledronic acid infusion on electrocardiographic parameters in patients with osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2016, Volume: 27, Issue:12 Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Electrocardiography; Female; Humans; Imidazoles; Male; Osteoporosis; Zoledronic Acid	2016
Undetectable Urine Calcium in a Gastric Bypass Patient. Clinical chemistry, 2016, Volume: 62, Issue:8 Topics: Bone Density Conservation Agents; Calcitriol; Calcium; Diphosphonates; Female; Gastric Bypass; Gastrointestinal Absorption; Humans; Imidazoles; Middle Aged; Osteoporosis; Zoledronic Acid	2016
Orbital Inflammation Secondary to Zoledronic Acid, a Rare Presentation. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2016, Volume: 22, Issue:7 Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Glucocorticoids; Humans; Imidazoles; Magnetic Resonance Imaging; Orbital Diseases; Osteoporosis; Prednisone; Zoledronic Acid	2016
PTH(1-34) and zoledronic acid have differing longitudinal effects on juvenile mouse femur strength and morphology. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2017, Volume: 35, Issue:8 Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Drug Evaluation, Preclinical; Female; Femur; Growth; Imidazoles; Mice, Inbred BALB C; Osteoporosis; Parathyroid Hormone; Random Allocation; Zoledronic Acid	2017
Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2017, Volume: 32, Issue:3 Topics: Cohort Studies; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Incidence; Male; Middle Aged; Osteoporosis; Zoledronic Acid	2017
Medication selection and patient compliance in the clinical management of osteoporosis. Australian family physician, 2016, Volume: 45, Issue:11 Topics: Australia; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Patient Compliance; Physician-Patient Relations; Reminder Systems; Risedronic Acid; Zoledronic Acid	2016
First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy. Joint bone spine, 2017, Volume: 84, Issue:2 Topics: Aged; Bone Density Conservation Agents; Calcium Pyrophosphate; Chondrocalcinosis; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis; Zoledronic Acid	2017
Novel therapeutic intervention for osteoporosis prepared with strontium hydroxyapatite and zoledronic acid: In vitro and pharmacodynamic evaluation. Materials science & engineering. C, Materials for biological applications, 2017, Feb-01, Volume: 71 Topics: Adsorption; Animals; Biomarkers; Biomechanical Phenomena; Bone Remodeling; Cancellous Bone; Diphosphonates; Drug Liberation; Female; Femur; Hydroxyapatites; Imidazoles; Nanoparticles; Osteoporosis; Rats, Wistar; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Strontium; X-Ray Diffraction; X-Ray Microtomography; Zoledronic Acid	2017
Clomipramine causes osteoporosis by promoting osteoclastogenesis via E3 ligase Itch, which is prevented by Zoledronic acid. Scientific reports, 2017, 02-01, Volume: 7 Topics: Animals; Bone Marrow Cells; Bone Resorption; Cell Count; Clomipramine; Diphosphonates; Imidazoles; Mice, Inbred C57BL; Organ Size; Osteoclasts; Osteogenesis; Osteoporosis; Ubiquitin-Protein Ligases; Zoledronic Acid	2017
[Zoledronic acid for preventing fractures]. Der Internist, 2008, Volume: 49, Issue:8 Topics: Aged; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis; Survival Analysis; Treatment Outcome; Zoledronic Acid	2008
Bisphosphonate-related osteonecrosis of the jaws--report of 2 cases and strategies on prevention and management. Quintessence international (Berlin, Germany : 1985), 2008, Volume: 39, Issue:3 Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Hyperbaric Oxygenation; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; Tooth Extraction; Zoledronic Acid	2008
Maximizing effectiveness of bisphosphonate therapy for osteoporosis. Southern medical journal, 2008, Volume: 101, Issue:8 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Imidazoles; Medication Adherence; Osteoporosis; Physician-Patient Relations; Risedronic Acid; Risk Factors; Zoledronic Acid	2008
Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study. European cells & materials, 2008, Jul-31, Volume: 16 Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Drug Delivery Systems; Female; Femur; Imidazoles; Implants, Experimental; Osteoporosis; Pilot Projects; Sheep; Treatment Outcome; Zoledronic Acid	2008
The effect of zoledronic acid on the intrinsic material properties of healing bone: an indentation study. Medical engineering & physics, 2008, Volume: 30, Issue:7 Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Elasticity; Fracture Healing; Fractures, Bone; Humans; Imidazoles; Models, Statistical; Osteoporosis; Pressure; Rats; Salts; Zoledronic Acid	2008
Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells. European journal of pharmacology, 2008, Dec-14, Volume: 600, Issue:1-3 Topics: 3T3 Cells; Alendronate; Animals; Bone Density Conservation Agents; Calcium; Calcium Channels, L-Type; Cattle; Cell Line; Diabetes Complications; Diphosphonates; Dose-Response Relationship, Drug; Glycation End Products, Advanced; Imidazoles; Mice; Osteoblasts; Osteoporosis; Pamidronate; Rats; Reactive Oxygen Species; Serum Albumin, Bovine; Time Factors; Zoledronic Acid	2008
[Bisphosphonates for osseus invasion caused by bronchial carcinoma]. Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:48 Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bronchial Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Osteoporosis; Zoledronic Acid	2008
Unilateral anterior uveitis complicating zoledronic acid therapy in prostate cancer. The Journal of rheumatology, 2008, Volume: 35, Issue:12 Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Diphosphonates; Goserelin; Humans; Imidazoles; Male; Osteoporosis; Uveitis, Anterior; Zoledronic Acid	2008
Determination of rat vertebral bone compressive fatigue properties in untreated intact rats and zoledronic-acid-treated, ovariectomized rats. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:8 Topics: Animals; Bone Density Conservation Agents; Compressive Strength; Diphosphonates; Female; Imidazoles; Osteoporosis; Ovariectomy; Rats; Rats, Wistar; Spinal Fractures; Spine; X-Ray Microtomography; Zoledronic Acid	2009
[New bisphosphonates and trends in drug therapy for osteoporosis: preface]. Clinical calcium, 2009, Volume: 19, Issue:1 Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Zoledronic Acid	2009
[Once-yearly administration of zoledronic acid to treat post-menopausal osteoporosis]. Der Unfallchirurg, 2009, Volume: 112, Issue:3 Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Osteoporosis; Postmenopause; Zoledronic Acid	2009
Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2009, Volume: 24, Issue:9 Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Osteoporosis; Peptide Fragments; Postmenopause; Procollagen; Zoledronic Acid	2009
Glucocorticoid-induced osteoporosis: hope on the HORIZON. Lancet (London, England), 2009, Apr-11, Volume: 373, Issue:9671 Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Osteoblasts; Osteoporosis; Research Design; Risedronic Acid; Treatment Outcome; Zoledronic Acid	2009
Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica, 2009, Volume: 94, Issue:5 Topics: Absorptiometry, Photon; Acid Phosphatase; Adult; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Isoenzymes; Male; Middle Aged; Osteocalcin; Osteopontin; Osteoporosis; Osteoprotegerin; Peptides; Randomized Controlled Trials as Topic; Tartrate-Resistant Acid Phosphatase; Thalassemia; Treatment Outcome; Young Adult; Zoledronic Acid	2009
Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clinical oral investigations, 2010, Volume: 14, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Connective Tissue; Diphosphonates; Female; Humans; Imidazoles; Inflammation; Jaw; Jaw Diseases; Male; Mandibular Diseases; Maxillary Diseases; Microscopy, Electron, Scanning; Middle Aged; Osteomyelitis; Osteonecrosis; Osteoporosis; Osteoradionecrosis; Pamidronate; Time Factors; Zoledronic Acid	2010
Multimodal therapy for vertebral involvement of systemic mastocytosis. Spine, 2009, Aug-01, Volume: 34, Issue:17 Topics: Adult; Back Pain; Biomarkers; Biopsy; Bone Density; Bone Density Conservation Agents; Diphosphonates; Glucocorticoids; Histamine; Humans; Hypotension; Imidazoles; Male; Mast Cells; Mastocytosis, Systemic; Osteoporosis; Postoperative Complications; Prednisolone; Pressure; Proto-Oncogene Proteins c-kit; Spinal Fractures; Spine; Treatment Outcome; Vertebroplasty; Zoledronic Acid	2009
Corticosteroids: no drug prevention of fractures needed. Prescrire international, 2009, Volume: 18, Issue:102 Topics: Adrenal Cortex Hormones; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Steroids; Teriparatide; Vitamin D; Zoledronic Acid	2009
Detecting early bone changes using in vivo micro-CT in ovariectomized, zoledronic acid-treated, and sham-operated rats. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2010, Volume: 21, Issue:8 Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Imidazoles; Osteoporosis; Ovariectomy; Postoperative Period; Rats; Rats, Sprague-Dawley; Tibia; X-Ray Microtomography; Zoledronic Acid	2010
Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading. Bone, 2010, Volume: 46, Issue:1 Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Imidazoles; Osteogenesis; Osteoporosis; Ovariectomy; Rats; Risedronic Acid; Zoledronic Acid	2010
A single dose of zoledronic acid reverses the deleterious effects of glucocorticoids on titanium implant osseointegration. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2010, Volume: 21, Issue:10 Topics: Absorptiometry, Photon; Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Glucocorticoids; Imidazoles; Lumbar Vertebrae; Male; Methylprednisolone; Orthopedic Fixation Devices; Osseointegration; Osteoporosis; Prostheses and Implants; Rabbits; Tibia; Titanium; Zoledronic Acid	2010
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. Journal of the American Geriatrics Society, 2010, Volume: 58, Issue:2 Topics: Age Factors; Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Femoral Neck Fractures; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Medication Adherence; Osteoporosis; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid	2010
Effect of zoledronic acid on osseointegration of titanium implants: an experimental study in an ovariectomized rabbit model. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2010, Volume: 68, Issue:3 Topics: Absorptiometry, Photon; Animals; Bone Density Conservation Agents; Dental Implants; Device Removal; Diphosphonates; Female; Imidazoles; Injections, Intravenous; Osseointegration; Osteoporosis; Ovariectomy; Rabbits; Random Allocation; Tibia; Titanium; Torque; Zoledronic Acid	2010
[Assessment and treatment of osteoporotic hip fractures]. Ugeskrift for laeger, 2010, Mar-01, Volume: 172, Issue:9 Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Hip Fractures; Humans; Imidazoles; Life Style; Middle Aged; Osteoporosis; Practice Patterns, Physicians'; Risk Factors; Surveys and Questionnaires; Zoledronic Acid	2010
Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic. Internal medicine journal, 2011, Volume: 41, Issue:2 Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; Zoledronic Acid	2011
The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. Urology, 2010, Volume: 75, Issue:5 Topics: Aged; Androgen Antagonists; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Severity of Illness Index; Zoledronic Acid	2010
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. The New England journal of medicine, 2010, May-13, Volume: 362, Issue:19 Topics: Alendronate; Bone Density Conservation Agents; Confidence Intervals; Diphosphonates; Female; Femoral Fractures; Hip Fractures; Humans; Imidazoles; Osteoporosis; Randomized Controlled Trials as Topic; Zoledronic Acid	2010
Evolving data about subtrochanteric fractures and bisphosphonates. The New England journal of medicine, 2010, May-13, Volume: 362, Issue:19 Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Hip Fractures; Humans; Imidazoles; Osteoporosis; Zoledronic Acid	2010
[Primary hyperparathyroidism in a patient with Paget's bone disease]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2010, Volume: 57, Issue:4 Topics: Adenoma; Aged; Alkaline Phosphatase; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyroidism; Imidazoles; Osteitis Deformans; Osteoporosis; Parathyroid Hormone; Parathyroid Neoplasms; Parathyroidectomy; Radionuclide Imaging; Zoledronic Acid	2010
Intravenous zoledronic acid: what are the indications for male osteoporosis? Current osteoporosis reports, 2010, Volume: 8, Issue:1 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Male; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Risk Factors; Testosterone; Zoledronic Acid	2010
Glucocorticoid-induced osteoporosis: management update. Current osteoporosis reports, 2010, Volume: 8, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Glucocorticoids; Humans; Imidazoles; Male; Osteoporosis; RANK Ligand; Teriparatide; Zoledronic Acid	2010
Editorial comment. Urology, 2010, Volume: 75, Issue:5 Topics: Androgen Antagonists; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Severity of Illness Index; Zoledronic Acid	2010
Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. American journal of therapeutics, 2011, Volume: 18, Issue:5 Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Liver Cirrhosis, Biliary; Male; Middle Aged; Osteoporosis; Pamidronate; Retrospective Studies; Zoledronic Acid	2011
Zoledronic acid--once-yearly. Corticosteroid-induced osteoporosis: no benefit. Prescrire international, 2010, Volume: 19, Issue:106 Topics: Adrenal Cortex Hormones; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Osteoporosis; Randomized Controlled Trials as Topic; Zoledronic Acid	2010
Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2011, Volume: 29, Issue:3 Topics: Animals; Apoptosis; Bone Density Conservation Agents; Cell Survival; Diphosphonates; Disease Models, Animal; Estrogens; Female; Imidazoles; Osteocytes; Osteoporosis; Ovariectomy; Sheep; Zoledronic Acid	2011
Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone. Clinical rheumatology, 2011, Volume: 30, Issue:1 Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Humans; Imidazoles; Osteitis Deformans; Osteoporosis; Postmenopause; Remission Induction; Treatment Outcome; Zoledronic Acid	2011
The effects of estrogen deficiency and bisphosphonate treatment on tissue mineralisation and stiffness in an ovine model of osteoporosis. Journal of biomechanics, 2011, Feb-03, Volume: 44, Issue:3 Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Estrogens; Female; Imidazoles; Models, Animal; Osteoporosis; Ovariectomy; Sheep; Zoledronic Acid	2011
Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris. International journal of oral and maxillofacial surgery, 2011, Volume: 40, Issue:3 Topics: Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bone Density Conservation Agents; Carcinoma; Chronic Disease; Debridement; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Male; Maxillary Diseases; Maxillary Sinusitis; Middle Aged; Osteonecrosis; Osteoporosis; Osteotomy; Recurrence; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid	2011
Effect of zoledronic acid on acro-osteolysis and osteoporosis in a patient with Hajdu-Cheney syndrome. Yonsei medical journal, 2011, Volume: 52, Issue:3 Topics: Acro-Osteolysis; Adult; Bone Density Conservation Agents; Diphosphonates; Female; Hajdu-Cheney Syndrome; Humans; Imidazoles; Osteoporosis; Zoledronic Acid	2011
Seizures associated with zoledronic acid for osteoporosis. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:7 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Osteoporosis; Seizures; Zoledronic Acid	2011
Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: report of 2 cases. Head & neck, 2013, Volume: 35, Issue:1 Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Mandible; Maxilla; Middle Aged; Osteoporosis; Zoledronic Acid	2013
[Effects of zoledronic acid in the treatment of breast cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:4 Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Neoadjuvant Therapy; Osteoporosis; Zoledronic Acid	2011
Awareness and education of patients receiving bisphosphonates. Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2012, Volume: 40, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Dental Care; Dentist-Patient Relations; Dentists; Diphosphonates; Drug Labeling; Female; Gastrointestinal Diseases; Health Knowledge, Attitudes, Practice; Health Literacy; Humans; Imidazoles; Injections, Intravenous; Interprofessional Relations; Male; Middle Aged; Osteoporosis; Patient Education as Topic; Physician-Patient Relations; Physicians; Prostatic Neoplasms; Risk Factors; Zoledronic Acid	2012
Determination of zoledronic acid in human urine and blood plasma using liquid chromatography/electrospray mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2011, Jul-15, Volume: 879, Issue:22 Topics: Bone Density Conservation Agents; Chromatography, Liquid; Diazomethane; Diphosphonates; Female; Humans; Imidazoles; Linear Models; Osteoporosis; Reference Standards; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Trimethylsilyl Compounds; Zoledronic Acid	2011
Pharmacist-run zoledronic acid clinic. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2011, Aug-01, Volume: 68, Issue:15 Topics: Ambulatory Care Facilities; Bone Density Conservation Agents; Diphosphonates; Drug Monitoring; Female; Humans; Imidazoles; Osteoporosis; Patient Education as Topic; Pharmaceutical Services; Pharmacists; Zoledronic Acid	2011
Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis. Bone, 2011, Volume: 49, Issue:5 Topics: Absorptiometry, Photon; Adolescent; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Child; Child, Preschool; Diphosphonates; Female; Humans; Imidazoles; Male; Osteoporosis; Zoledronic Acid	2011
[Inflammation of the jaws during treatment with bisphosphonates]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:41 Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Drug Approval; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Opportunistic Infections; Osteomyelitis; Osteonecrosis; Osteoporosis; Pamidronate; Practice Guidelines as Topic; Risk Factors; Zoledronic Acid	2011
Data from extension trials: denosumab and zoledronic acid. Current osteoporosis reports, 2012, Volume: 10, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Comorbidity; Contraindications; Creatinine; Denosumab; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; RANK Ligand; Renal Insufficiency; Treatment Outcome; Zoledronic Acid	2012
Histopathological features of osteonecrosis of the jaw associated with bisphosphonates. Histopathology, 2012, Volume: 60, Issue:3 Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Mandible; Osteoporosis; Zoledronic Acid	2012
Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2012, Volume: 23, Issue:9 Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Male; Osteoporosis; Patient Compliance; Patient Satisfaction; Risk Factors; Surveys and Questionnaires; Treatment Outcome; Zoledronic Acid	2012
[Factors associated with acute febrile reaction in elderly patients receiving intravenous zoledronic acid for osteoporosis]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2011, Volume: 31, Issue:12 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; China; Diphosphonates; Female; Fever; Humans; Imidazoles; Incidence; Infusions, Intravenous; Male; Osteoporosis; Parathyroid Hormone; Zoledronic Acid	2011
Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. Bone, 2012, Volume: 50, Issue:3 Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Neurofibromatosis 1; Osteoclasts; Osteoporosis; Zoledronic Acid	2012
Bisphosphonate therapy for osteoporosis: the long and short of it. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2012, Volume: 27, Issue:2 Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis; Osteoporotic Fractures; Zoledronic Acid	2012
Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis care & research, 2012, Volume: 64, Issue:7 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Logistic Models; Male; Medicare; Medication Adherence; Osteoporosis; Patient Compliance; United States; Zoledronic Acid	2012
Osteopathology induced by bisphosphonates and dental implants: clinical observations. Clinical oral investigations, 2013, Volume: 17, Issue:1 Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Debridement; Dental Implants; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Male; Mandible; Mandibular Neoplasms; Maxilla; Neoplasms; Osteomyelitis; Osteoporosis; Pamidronate; Risk Factors; Time Factors; Zoledronic Acid	2013
Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence? Singapore medical journal, 2012, Volume: 53, Issue:3 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Diphosphonates; Femoral Fractures; Follow-Up Studies; Fracture Fixation, Intramedullary; Fracture Healing; Fractures, Spontaneous; Humans; Imidazoles; Male; Neoplasm Staging; Orchiectomy; Osteoporosis; Prostatectomy; Prostatic Neoplasms; Radiography; Risk Assessment; Zoledronic Acid	2012
Zoledronic acid improves bone mineral density in pediatric spinal cord injury. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2012, Volume: 27, Issue:7 Topics: Bone and Bones; Bone Density; Child; Densitometry; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Myelitis, Transverse; Osteoporosis; Spinal Cord Injuries; Tibia; Treatment Outcome; Zoledronic Acid	2012
Atypical insufficiency type femoral stress fractures in patient on bisphosphonates. Medicine and health, Rhode Island, 2012, Volume: 95, Issue:2 Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; Fractures, Stress; Humans; Imidazoles; Osteoporosis; Zoledronic Acid	2012
Orthodontic tooth movement and root resorption in ovariectomized rats treated by systemic administration of zoledronic acid. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics, 2012, Volume: 141, Issue:5 Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Osteoporosis; Postmenopause; Rats; Rats, Wistar; Root Resorption; Tooth Movement Techniques; Zoledronic Acid	2012
[When should bisphosphonate treatment be discontinued?]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2012, Aug-07, Volume: 132, Issue:14 Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Risk Factors; Zoledronic Acid	2012
[Should we treat thalassemia-induced osteoporosis: two case reports]. Praxis, 2012, Oct-03, Volume: 101, Issue:20 Topics: Absorptiometry, Photon; Adult; Antibodies, Monoclonal, Humanized; beta-Thalassemia; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Hypogonadism; Imidazoles; Infusions, Intravenous; Male; Osteoporosis; Zoledronic Acid	2012
Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2013, Volume: 28, Issue:4 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Biomarkers; Biomechanical Phenomena; Bone and Bones; Bone Remodeling; Diphosphonates; Female; Finite Element Analysis; Humans; Imidazoles; Middle Aged; Osteoporosis; Parathyroid Hormone; Postmenopause; Radius; Tibia; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid	2013
Long-term effects of amino-bisphosphonates on circulating γδ T cells. Calcified tissue international, 2012, Volume: 91, Issue:6 Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Lymphocyte Subsets; Male; Middle Aged; Osteoporosis; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Time Factors; Zoledronic Acid	2012
Variations in nanomechanical properties and tissue composition within trabeculae from an ovine model of osteoporosis and treatment. Bone, 2013, Volume: 52, Issue:1 Topics: Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Imidazoles; Nanotechnology; Osteoporosis; Raloxifene Hydrochloride; Sheep; Spectrum Analysis, Raman; Zoledronic Acid	2013
Drug-induced dermatomyositis after zoledronic acid. The Australasian journal of dermatology, 2012, Volume: 53, Issue:4 Topics: Bone Density Conservation Agents; Dermatomyositis; Diphosphonates; Drug Eruptions; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Zoledronic Acid	2012
Avascular necrosis of the proximal carpal row of the wrist. A possible complication of bisphosphonate administration. Chirurgie de la main, 2012, Volume: 31, Issue:6 Topics: Bone Density Conservation Agents; Carpal Bones; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteonecrosis; Osteoporosis; Risk Factors; Treatment Outcome; Wrist; Zoledronic Acid	2012
Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Cancer discovery, 2013, Volume: 3, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Diphosphonates; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Molecular Structure; Oligopeptides; Osteoclasts; Osteoporosis; Xenograft Model Antitumor Assays; Zoledronic Acid	2013
Promotion of peri-implant bone healing by systemically administered parathyroid hormone (1-34) and zoledronic acid adsorbed onto the implant surface. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2013, Volume: 24, Issue:3 Topics: Animals; Bone Density Conservation Agents; Coated Materials, Biocompatible; Diphosphonates; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Imidazoles; Implants, Experimental; Osseointegration; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Shear Strength; Stress, Mechanical; Teriparatide; Tibia; X-Ray Microtomography; Zoledronic Acid	2013
Prostate cancer and osteoporosis. Current osteoporosis reports, 2013, Volume: 11, Issue:1 Topics: Adenocarcinoma; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Risk Factors; Zoledronic Acid	2013
Bisphosphonates in prostate cancer: where are we and where should we go? Journal of the National Cancer Institute, 2003, Sep-03, Volume: 95, Issue:17 Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Osteoporosis; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid	2003
Clinical trials test bisphosphonates in hormone-sensitive prostate cancer. Journal of the National Cancer Institute, 2003, Sep-03, Volume: 95, Issue:17 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Male; Multicenter Studies as Topic; Neoplasm Staging; Neoplasms, Hormone-Dependent; Osteoporosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Zoledronic Acid	2003
[Prostatic carcinoma. Zoledronic acid raises bone density]. Aktuelle Urologie, 2003, Volume: 34, Issue:7 Topics: Bone Density; Densitometry; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Male; Multicenter Studies as Topic; Osteoporosis; Placebos; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Zoledronic Acid	2003
Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid. British journal of haematology, 2004, Volume: 125, Issue:1 Topics: Adult; beta-Thalassemia; Diphosphonates; Female; Humans; Imidazoles; Insulin-Like Growth Factor I; Male; Osteoporosis; Zoledronic Acid	2004
Highlights from the 98th annual meeting of the American Urological Association Chicago, IL. Clinical prostate cancer, 2003, Volume: 2, Issue:1 Topics: Androgen Antagonists; Cancer Vaccines; Clinical Trials, Phase II as Topic; Congresses as Topic; Controlled Clinical Trials as Topic; Diphosphonates; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imidazoles; Male; Osteoporosis; Prognosis; Prostatic Neoplasms; Societies, Medical; Survival Analysis; Tomography, Emission-Computed; Treatment Outcome; United States; Urology; Zoledronic Acid	2003
The effect of intravenous zoledronic acid on glucocorticoid-induced multiple vertebral fractures in juvenile systemic lupus erythematosus. Revista do Hospital das Clinicas, 2004, Volume: 59, Issue:5 Topics: Adolescent; Azathioprine; Bone Density; Bone Density Conservation Agents; Cervical Vertebrae; Diphosphonates; Female; Glucocorticoids; Humans; Imidazoles; Lupus Erythematosus, Systemic; Osteoporosis; Prednisone; Spinal Fractures; Zoledronic Acid	2004
[Rapid drug information]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2005, Volume: 48, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Information Services; Germany; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Risk Assessment; Zoledronic Acid	2005
Longer-lasting osteoporosis drugs sought. JAMA, 2005, May-25, Volume: 293, Issue:20 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide; Zoledronic Acid	2005
Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update. Medicina oral, patologia oral y cirugia bucal, 2005, Jul-01, Volume: 10 Suppl 2 Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid	2005
Osteonecrosis of the jaw and bisphosphonates. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Alendronate; Animals; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid	2005
Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2005, Volume: 20, Issue:10 Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cartilage; Child; Child, Preschool; Diaphyses; Diphosphonates; Humans; Imidazoles; Osteogenesis Imperfecta; Osteoporosis; Rabbits; Tibia; Time Factors; Zoledronic Acid	2005
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2005, Volume: 63, Issue:11 Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Dental Caries; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hyperostosis; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Osteoporosis; Pamidronate; Periodontitis; Prostatic Neoplasms; Risk Factors; Tooth Extraction; Zoledronic Acid	2005
Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats. Journal of biomedical materials research. Part A, 2006, Volume: 76, Issue:1 Topics: Animals; Biomechanical Phenomena; Bone and Bones; Coated Materials, Biocompatible; Diphosphonates; Female; Humans; Imidazoles; Microscopy, Electron, Scanning; Osteoporosis; Prostheses and Implants; Rats; Rats, Wistar; Surface Properties; Zoledronic Acid	2006
[Osteoporosis and anti-androgenic therapy in case of prostate cancer]. Revue medicale suisse, 2005, Oct-05, Volume: 1, Issue:35 Topics: Androgen Antagonists; Bone Resorption; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Osteoporosis; Prognosis; Prostatic Neoplasms; Risk Factors; Survival; Zoledronic Acid	2005
Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer. BMC cancer, 2005, Dec-06, Volume: 5 Topics: Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Uveitis, Anterior; Zoledronic Acid	2005
Summaries for patients. Zolendronic acid prevents bone loss after liver transplantation. Annals of internal medicine, 2006, Feb-21, Volume: 144, Issue:4 Topics: Bone Density; Bone Density Conservation Agents; Chronic Disease; Diphosphonates; Double-Blind Method; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Liver Failure; Liver Transplantation; Osteoporosis; Zoledronic Acid	2006
"The beneficial effects of zoledronic acid therapy following an acute stroke in rats" by Lee et al. Bone, 2006, Volume: 39, Issue:5 Topics: Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Imidazoles; Osteoporosis; Rats; Stroke; Zoledronic Acid	2006
A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats. Bone, 2006, Volume: 39, Issue:4 Topics: Animals; Aromatase Inhibitors; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Estrogens; Female; Imidazoles; Injections, Intravenous; Letrozole; Nitriles; Organ Size; Osteocalcin; Osteoporosis; Ovariectomy; RANK Ligand; Rats; Rats, Wistar; Triazoles; Uterus; Zoledronic Acid	2006
Experimental evaluation of the effects of zoledronic acid on regenerate bone formation and osteoporosis in mandibular distraction osteogenesis. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2006, Volume: 64, Issue:8 Topics: Absorptiometry, Photon; Animals; Bone Density; Bone Density Conservation Agents; Bone Regeneration; Diphosphonates; Imidazoles; Male; Mandible; Mandibular Advancement; Osteogenesis, Distraction; Osteoporosis; Rabbits; Random Allocation; Zoledronic Acid	2006
Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clinic proceedings, 2006, Volume: 81, Issue:8 Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Oral Surgical Procedures; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid	2006
Zoledronic acid for the treatment of thalassemia-induced osteonecrosis. Haematologica, 2006, Volume: 91, Issue:9 Topics: beta-Thalassemia; Diphosphonates; Dose-Response Relationship, Drug; Humans; Imidazoles; Osteonecrosis; Osteoporosis; Zoledronic Acid	2006
A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1 Topics: Acute-Phase Reaction; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Humans; Imidazoles; Incidence; Osteoporosis; Zoledronic Acid	2007
Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2007, Volume: 25, Issue:3 Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Infectious; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Female; Imidazoles; Interleukin-6; Mice; Osteoclasts; Osteoporosis; Staphylococcal Infections; Staphylococcus aureus; Zoledronic Acid	2007
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta bio-medica : Atenei Parmensis, 2006, Volume: 77, Issue:2 Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conservation Agents; Bone Neoplasms; Chlorhexidine; Curettage; Diphosphonates; Female; Humans; Hydrogen Peroxide; Imidazoles; Jaw Diseases; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Mouthwashes; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Radiography; Time Factors; Zoledronic Acid	2006
Annual zoledronic acid: is less more? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-20, Volume: 25, Issue:9 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2007
Paraplegia due to extramedullary hematopoiesis in thalassemia treated successfully with radiation therapy. Haematologica, 2007, Volume: 92, Issue:3 Topics: Adult; beta-Thalassemia; Blood Transfusion; Calcium; Cobalt Radioisotopes; Contraindications; Decompression, Surgical; Diphosphonates; Epidural Space; Folic Acid; Fractures, Spontaneous; Hematopoiesis, Extramedullary; Humans; Imidazoles; Male; Osteoporosis; Paraplegia; Radioisotope Teletherapy; Spinal Cord Compression; Zoledronic Acid	2007
Effects of bisphosphonate treatment on bone repair under immunosuppression using cyclosporine A in adult rats. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2007, Volume: 18, Issue:11 Topics: Animals; Biomarkers; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Bone Transplantation; Cyclosporine; Diphosphonates; Drug Interactions; Fractures, Bone; Graft Survival; Imidazoles; Immunosuppressive Agents; Male; Osteogenesis; Osteoporosis; Rats; Rats, Inbred Lew; Tibia; Zoledronic Acid	2007
Bisphosphonates and osteonecrosis of the jaw. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:7 Topics: Bone Remodeling; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Neoplasms; Osteonecrosis; Osteoporosis; Pamidronate; Zoledronic Acid	2007
Bone turnover 18 months after a single intravenous dose of zoledronic acid. International journal of clinical practice, 2007, Volume: 61, Issue:6 Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Male; Middle Aged; Osteoporosis; Prospective Studies; Risk Factors; Treatment Outcome; Zoledronic Acid	2007
Bone density in breast cancer: when to intervene? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22 Topics: Absorptiometry, Photon; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Goserelin; Humans; Imidazoles; Nitriles; Osteoporosis; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid	2007
Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Boston; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Zoledronic Acid	2007
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2008, Volume: 62, Issue:2 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Case-Control Studies; Cathepsin K; Cathepsins; Cystatin C; Cystatins; Diphosphonates; Disease Progression; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Prostatic Hyperplasia; Prostatic Neoplasms; ROC Curve; Zoledronic Acid	2008
Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint bone spine, 2008, Volume: 75, Issue:1 Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Middle Aged; Multiple Myeloma; Orthognathic Surgical Procedures; Osteonecrosis; Osteoporosis; Pamidronate; Prospective Studies; Zoledronic Acid	2008
[Advances in the field of osteoporosis]. La Revue du praticien, 2007, Oct-15, Volume: 57, Issue:15 Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Female; Glucocorticoids; Humans; Hypogonadism; Imidazoles; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Teriparatide; Thiophenes; Zoledronic Acid	2007
Development of a low-dose anti-resorptive drug regimen reveals synergistic suppression of bone formation when coupled with disuse. Journal of applied physiology (Bethesda, Md. : 1985), 2008, Volume: 104, Issue:3 Topics: Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Bone Resorption; Calcification, Physiologic; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Femur; Hindlimb Suspension; Imidazoles; Mice; Mice, Inbred C57BL; Osteoblasts; Osteogenesis; Osteoporosis; Osteoprotegerin; Space Flight; Tomography, X-Ray Computed; Weightlessness Countermeasures; Zoledronic Acid	2008
Consultation corner. Bone loss drug gives users a break. The Johns Hopkins medical letter health after 50, 2007, Volume: 19, Issue:10 Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis; Vitamin D; Zoledronic Acid	2007
Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography. Calcified tissue international, 2008, Volume: 82, Issue:3 Topics: Animals; Bone Demineralization, Pathologic; Bone Density Conservation Agents; Bone Resorption; Compressive Strength; Diphosphonates; Disease Models, Animal; Elasticity; Female; Imidazoles; Osteoporosis; Ovariectomy; Rats; Rats, Wistar; Stress, Mechanical; Tibia; Tomography, X-Ray Computed; Zoledronic Acid	2008
New annual osteoporosis drug reduces risk of death, future fractures. Infused dose is more convenient for patients, enhances overall quality of life. DukeMedicine healthnews, 2007, Volume: 13, Issue:12 Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Hip Fractures; Humans; Imidazoles; Life Style; Osteoporosis; Zoledronic Acid	2007
[Zoledronic acid for preventing fractures. HORIZON trial (Health Outcomes and Reduced Incidence with Zoledronic acid ONce yearly)]. Der Internist, 2008, Volume: 49, Issue:4 Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Male; Osteoporosis; Randomized Controlled Trials as Topic; Secondary Prevention; Zoledronic Acid	2008
[Osteoporosis--new therapeutic possibilities. The Danish Bone Society]. Ugeskrift for laeger, 2008, Mar-17, Volume: 170, Issue:12 Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis; Zoledronic Acid	2008
Multiple bone lesions resembling a metastatic origin. An unexpected diagnosis. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008, Volume: 10, Issue:4 Topics: Aged; Anemia; Back Pain; Bone Density Conservation Agents; Bone Neoplasms; Diagnosis, Differential; Diphosphonates; Female; Humans; Hypertension; Imidazoles; Immunologic Factors; Interferon-alpha; Magnetic Resonance Imaging; Mastocytosis, Systemic; Osteolysis; Osteoporosis; Radionuclide Imaging; Zoledronic Acid	2008
Histomorphometric evaluation of the effects of zoledronic acid on mandibular distraction osteogenesis in rabbits. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2008, Volume: 66, Issue:5 Topics: Animals; Bone Density Conservation Agents; Bone Regeneration; Calcification, Physiologic; Cell Proliferation; Collagen; Dental Stress Analysis; Diphosphonates; Fibroblasts; Imidazoles; Male; Mandible; Mandibular Advancement; Osteoblasts; Osteoclasts; Osteogenesis, Distraction; Osteoporosis; Rabbits; Random Allocation; Zoledronic Acid	2008
Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis. Annals of hematology, 2008, Volume: 87, Issue:11 Topics: Bone Density; Bone Density Conservation Agents; Cohort Studies; Diphosphonates; Genotype; Humans; Imidazoles; Osteoporosis; Polymorphism, Single Nucleotide; Receptors, Calcitriol; Thalassemia; Zoledronic Acid	2008
A once-yearly IV bisphosphonate for osteoporosis. Obstetrics and gynecology, 2008, Volume: 111, Issue:5 Topics: Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis; Zoledronic Acid	2008
Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Medical oncology (Northwood, London, England), 2009, Volume: 26, Issue:1 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cystatin C; Diphosphonates; Female; Humans; Imidazoles; Interleukin-6; Male; Middle Aged; Osteoporosis; Prostate-Specific Antigen; Prostatic Neoplasms; ROC Curve; Zoledronic Acid	2009
Zoledronate. British journal of clinical practice. Supplement, 1996, Volume: 87 Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteitis Deformans; Osteoporosis; Zoledronic Acid	1996
Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM). Breast cancer (Tokyo, Japan), 2000, Volume: 7, Issue:4 Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Osteoclasts; Osteoporosis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid	2000